long_drug,cas_no,db_name,dbid,ind,doid,ind_type,long_ind
111Indium pentetreotide,,,,neuroendocrine tumor,doid:169,original,Indium In-111 interdependent is an agent for the scintigraphic localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors.
111Indium pentetreotide,,,,neuroendocrine tumor,doid:169,repositioned,Treatment of neuroendocrine tumors 
4-aminosalicylic acid,65-49-6,Aminosalicylic Acid,DB00233,tuberculosis,doid:399,original,Treatment of tuberculosis
4-aminosalicylic acid,65-49-6,Aminosalicylic Acid,DB00233,Crohn's disease,doid:8778,repositioned,Treatment of Crohn's disease.
4-aminosalicylic acid,65-49-6,Aminosalicylic Acid,DB00233,ulcerative colitis,doid:8577,repositioned,Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.
Adalimumab,331731-18-1,Adalimumab,DB00051,rheumatoid arthritis,doid:7148,original,"1. Rheumatoid Arthritis - Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. 2. Psoriatic Arthritis - Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. 3. Ankylosing Spondylitis - Reducing signs and symptoms in patients with active disease. 4. Crohn_s Disease - Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn_s disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. 5. Plaque Psoriasis - The treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate."
Adalimumab,331731-18-1,Adalimumab,DB00051,psoriatic arthritis,doid:9008,original,"1. Rheumatoid Arthritis - Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. 2. Psoriatic Arthritis - Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. 3. Ankylosing Spondylitis - Reducing signs and symptoms in patients with active disease. 4. Crohn_s Disease - Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn_s disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. 5. Plaque Psoriasis - The treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate."
Adalimumab,331731-18-1,Adalimumab,DB00051,ankylosing spondylitis,doid:7147,original,"1. Rheumatoid Arthritis - Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. 2. Psoriatic Arthritis - Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. 3. Ankylosing Spondylitis - Reducing signs and symptoms in patients with active disease. 4. Crohn_s Disease - Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn_s disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. 5. Plaque Psoriasis - The treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate."
Adalimumab,331731-18-1,Adalimumab,DB00051,Crohn's disease,doid:8778,original,"1. Rheumatoid Arthritis - Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. 2. Psoriatic Arthritis - Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. 3. Ankylosing Spondylitis - Reducing signs and symptoms in patients with active disease. 4. Crohn_s Disease - Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn_s disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. 5. Plaque Psoriasis - The treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate."
Adalimumab,331731-18-1,Adalimumab,DB00051,psoriasis,doid:8893,original,"1. Rheumatoid Arthritis - Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. 2. Psoriatic Arthritis - Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. 3. Ankylosing Spondylitis - Reducing signs and symptoms in patients with active disease. 4. Crohn_s Disease - Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn_s disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. 5. Plaque Psoriasis - The treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate."
Adalimumab,331731-18-1,Adalimumab,DB00051,juvenile rheumatoid arthritis,doid:676,original,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older. It can be used alone or in combination with methotrexate.
Adalimumab,331731-18-1,Adalimumab,DB00051,Crohn's disease,doid:8778,repositioned,Treatment of pediatric Crohn's disease.
Adenosine,58-61-7,Adenosine,DB00640,Lown-Ganong-Levine syndrome,doid:13087,original,"Conversion to sinus rhythm of paroxysmal supraventricular tachycardia, including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome)."
Adenosine,58-61-7,Adenosine,DB00640,brain cancer,doid:1319,repositioned,For use in conjunction with BCNU in the treatment of brain tumors.
Albuterol,18559-94-9,Salbutamol,DB01001,chronic obstructive pulmonary disease,doid:3083,original,"For the prevention and relief of bronchospasm in patients with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm."
Albuterol,18559-94-9,Salbutamol,DB01001,central nervous system disease,doid:331,repositioned,Prevention of paralysis due to spinal cord injury
Aldesleukin,85898-30-2,Aldesleukin,DB00041,renal cell carcinoma,doid:4450,original,Treatment of adults (>18 years old) with metastatic renal cell carcinoma.
Aldesleukin,85898-30-2,Aldesleukin,DB00041,melanoma,doid:1909,original,Treatment of adults with metastatic melanoma.
Aldesleukin,85898-30-2,Aldesleukin,DB00041,non-Hodgkin lymphoma,doid:0060060,repositioned,For the treatment non-Hodgkin's lymphoma.
Aldesleukin,85898-30-2,Aldesleukin,DB00041,acute myeloid leukemia,doid:9119,repositioned,Treatment of acute myelogenous leukemia.
Aldesleukin,85898-30-2,Aldesleukin,DB00041,primary immunodeficiency disease,doid:612,repositioned,Treatment of primary immunodeficiency disease associated with T-cell defects.
Alefacept,222535-22-0,Alefacept,DB00092,psoriasis,doid:8893,original,Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Alefacept,222535-22-0,Alefacept,DB00092,Transplant Rejection,,repositioned,For use as prophylaxis of rejection in patients receiving allogenic solid organ transplants.
Alendronate,66376-36-1,Alendronic acid,DB00630,osteoporosis,doid:11476,original,Treatment and prevention of osteoporosis in postmenopausal women; Treatment to increase bone mass in men with osteoporosis. Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density;Treatment of Paget_s disease of bone in men and women.
Alendronate,66376-36-1,Alendronic acid,DB00630,osteogenesis imperfecta,doid:12347,repositioned,Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older
Alendronate,66376-36-1,Alendronic acid,DB00630,Gaucher's disease,doid:1926,repositioned,Treatment of the bone manifestations of Gaucher disease
Alfentanil,71195-58-9,Alfentanil,DB00802,**Analgesic**,,original,Alfentanil Injection is indicated: as an analgesic adjunct given in incremental doses in the maintenance of anesthesia with barbiturate/nitrous oxide/oxygen; as an analgesic administered by continuous infusion with nitrous oxide/oxygen in the maintenance of general anesthesia; as a primary anesthetic agent for the induction of anesthesia in patients undergoing general surgery in which endotracheal intubation and mechanical ventilation are required; as the analgesic component for monitored anesthesia care.
Alfentanil,71195-58-9,Alfentanil,DB00802,neuropathy,doid:870,repositioned,Treatment of painful HIV-associated neuropathy
Alglucerase injection,37228-64-1,Taliglucerase Alfa,DB08876,Gaucher's disease,doid:1926,original,"Use as a long-term enzyme replacement therapy for children, adolescents and adult patients with a confirmed diagnosis of Type I Gaucher disease who exhibit signs and symptoms that are severe enough to result in one or more of the following conditions: a. moderate-to-severe anemia; b. thrombocytopenia with bleeding tendency;  c. bone disease;  d.significant hepatomegaly or splenomegaly."
Alglucerase injection,37228-64-1,Taliglucerase Alfa,DB08876,Gaucher's disease,doid:1926,repositioned,Replacement therapy in patients with Type II and III Gaucher's disease.
Alitretinoin,9009-81-8,Alitretinoin,DB00523,Kaposi's sarcoma,doid:8632,original,Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.
Alitretinoin,9009-81-8,Alitretinoin,DB00523,acute promyelocytic leukemia,doid:0060318,repositioned,Treatment of acute promyelocytic leukemia
Allopurinol,315-30-0,Allopurinol,DB00437,lymphatic system cancer,doid:0060073,original,"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy."
Allopurinol,315-30-0,Allopurinol,DB00437,gout,doid:13189,original,"Management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis and/or nephropathy); Management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800  mg/day  in  male patients and 750 mg/day in female patients."
Allopurinol,315-30-0,Allopurinol,DB00437,**organ preservation**,,repositioned,Ex-vivo preservation of cadaveric kidneys for transplantation
Allopurinol,315-30-0,Allopurinol,DB00437,Chagas disease,doid:12140,repositioned,Treatment of Chagas' disease.
Allopurinol,315-30-0,Allopurinol,DB00437,leishmaniasis,doid:9065,repositioned,Treatment of cutaneous and visceral leishmaniasis.
Alpha1-Proteinase Inhibitor (Human),9041-92-3,Alpha-1-proteinase inhibitor,DB00058,pulmonary emphysema,doid:9675,original,For chronic replacement therapy of individuals having congenital deficiency of alpha1- proteinase inhibitor with clinically demonstrable panacinar emphysema.
Alpha1-Proteinase Inhibitor (Human),9041-92-3,Alpha-1-proteinase inhibitor,DB00058,alpha 1-antitrypsin deficiency,doid:13372,repositioned,Inhalation therapy for the the treatment of congential deficiency of alpha1-proteinase inhibitor.
Alpha1-Proteinase Inhibitor (Human),9041-92-3,Alpha-1-proteinase inhibitor,DB00058,lung disease,doid:850,repositioned,Prevention of bronchopulmonary dysplasia
Alpha1-Proteinase Inhibitor (Human),9041-92-3,Alpha-1-proteinase inhibitor,DB00058,chronic obstructive pulmonary disease,doid:3083,repositioned,To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis
Alpha1-Proteinase Inhibitor (Human),9041-92-3,Alpha-1-proteinase inhibitor,DB00058,bronchiectasis,doid:9563,repositioned,Treatment of bronchiectasis
Alpha1-Proteinase Inhibitor (Human),9041-92-3,Alpha-1-proteinase inhibitor,DB00058,cystic fibrosis,doid:1485,repositioned,Treatment of cystic fibrosis
Alpha1-Proteinase Inhibitor (Human),9041-92-3,Alpha-1-proteinase inhibitor,DB00058,pulmonary emphysema,doid:9675,repositioned,Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency.
Alprostadil,745-65-3,Alprostadil,DB00770,impotence,doid:1875,original,"Treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology."
Alprostadil,745-65-3,Alprostadil,DB00770,postherpetic neuralgia,,repositioned,Management of postherpetic neuralgia
Alprostadil,745-65-3,Alprostadil,DB00770,peripheral vascular disease,doid:341,repositioned,"Treatment of severe peripheral arterial occlusive disease (critical limb ischemia) in patients where other procedures, grafts or angioplasty, are not indicated."
Alteplase,105857-23-6,Alteplase,DB00009,,,original,Restoration of funciton to central venous access devices as assessed by the ability to withdraw blood.
Alteplase,105857-23-6,Alteplase,DB00009,Intraventricular hemmorage,,repositioned,Treatment of intraventricular hemmorage associated with intracerebral hemmorrhage
Ambrisentan,177036-94-1,Ambrisentan,DB06403,pulmonary hypertension,doid:6432,original,Treatment of pulmonary arterial hypertension (WHO group I) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening
Ambrisentan,177036-94-1,Ambrisentan,DB06403,idiopathic pulmonary fibrosis,doid:0050156,repositioned,Treatment of idiopathic pulmonary fibrosis
Amifostine,20537-88-6,Amifostine,DB01143,xerostomia,,original,"Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands. "
Amifostine,20537-88-6,Amifostine,DB01143,toxicity,,repositioned,For the reduction of the incidence and severity of toxicities associated with cisplatin administration.  
Amifostine,20537-88-6,Amifostine,DB01143,myelodysplastic syndrome,doid:0050908,repositioned,Treatment of myelodysplastic syndromes.  
Amiloride HCl solution for inhalation,2016-88-8,Amiloride,DB00594,hypokalemia,doid:4500,original,"As adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension to: help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic; prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias."
Amiloride HCl solution for inhalation,2016-88-8,Amiloride,DB00594,cystic fibrosis,doid:1485,repositioned,Treatment of cystic fibrosis.
Aminocaproic acid,60-32-2,Aminocaproic Acid,DB00513,fibrinolysis,,original,Useful in enhancing hemostasis when fibrinolysis contributes to bleeding.
Aminocaproic acid,60-32-2,Aminocaproic Acid,DB00513,hyphema,,repositioned,For the topical treatment of traumatic hyphema of the eye.
Aminolevulinic acid hydrochloride,106-60-5,Aminolevulinic acid,DB00855,actinic keratosis,doid:8866,original,"The LEVULAN KERASTICK for Topical Solution, a porphyrin precursor, plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp."
Aminolevulinic acid hydrochloride,106-60-5,Aminolevulinic acid,DB00855,esophagus carcinoma in situ,doid:9095,repositioned,Treatment of esophageal dysplasia
Aminosidine,1263-89-4,Paromomycin,DB01421,amebiasis,doid:9181,original,It is indicated for intestinal amebiasis__acute and chronic.
Aminosidine,1263-89-4,Paromomycin,DB01421,hepatic coma,doid:12550,original,It is indicated for management of hepatic coma__as adjunctive therapy.
Aminosidine,1263-89-4,Paromomycin,DB01421,Mycobacterium avium complex disease,doid:2755,repositioned,Treatment of Mycobacterium avium complex.
Aminosidine,1263-89-4,Paromomycin,DB01421,tuberculosis,doid:399,repositioned,Treatment of tuberculosis.
Aminosidine,1263-89-4,Paromomycin,DB01421,visceral leishmaniasis,doid:9146,repositioned,Treatment of visceral leishmaniasis (kala-azar).
Anagrelide,68475-42-3,Anagrelide,DB00261,hemorrhagic thrombocythemia,doid:2224,original,Treatment of patients with essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms.
Anagrelide,68475-42-3,Anagrelide,DB00261,polycythemia vera,doid:8997,repositioned,Treatment of polycythemia vera.
Anti-tac (human),152923-56-3,Daclizumab,DB00111,Transplant Rejection,,original,"Prophylaxis of acute organ rejection in patients receiving renal transplants, to be used as a part of an immunosuppressive  regimen that includes cyclosporine and corticosteroids."
Anti-tac (human),152923-56-3,Daclizumab,DB00111,graft vs host disease,,repositioned,Prevention of acute graft-vs-host disease following bone marrow transplantation.
Apomorphine,41372-20-7,Apomorphine,DB00714,hypomobility,,original,"For the acute, intermittent treatment of hypomobility, _off_ episodes (_end-of-dose wearing off_ and unpredictable _on/off_ episodes) associated with advanced Parkinson_s disease. "
Apomorphine,41372-20-7,Apomorphine,DB00714,traumatic brain injury,,repositioned,For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous).
Arcitumomab,154361-48-5,Arcitumomab,DB00113,**diagnostic agent**,,original,"Useful for the detection of presence, location, and extent of recurrent and metastatic colorectal adenocarcinoma involving the liver, extrahepatic abdomen, and pelvis."
Arcitumomab,154361-48-5,Arcitumomab,DB00113,**diagnostic agent**,,repositioned,"Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma."
Aripiprazole,129722-12-9,Aripiprazole,DB01238,schizophrenia,doid:5419,original,"A. as oral formulations for the: 1.Treatment of schizophrenia (Adults & Adolescents [ages 13-17]); 2. Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (Adults & Pediatric Patients [ages 10-17]), Maintenance treatment of bipolar I disorder (Adults); 3. Adjunctive treatment of major depressive disorder (Adults); 4.Treatment of irritability associated with autistic disorder (Pediatric Patients [ages 6-17 years]). B. as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (Adults)."
Aripiprazole,129722-12-9,Aripiprazole,DB01238,bipolar disorder,doid:3312,original,"A. as oral formulations for the: 1.Treatment of schizophrenia (Adults & Adolescents [ages 13-17]); 2. Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (Adults & Pediatric Patients [ages 10-17]), Maintenance treatment of bipolar I disorder (Adults); 3. Adjunctive treatment of major depressive disorder (Adults); 4.Treatment of irritability associated with autistic disorder (Pediatric Patients [ages 6-17 years]). B. as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (Adults)."
Aripiprazole,129722-12-9,Aripiprazole,DB01238,major depressive disorder,doid:1470,original,"A. as oral formulations for the: 1.Treatment of schizophrenia (Adults & Adolescents [ages 13-17]); 2. Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (Adults & Pediatric Patients [ages 10-17]), Maintenance treatment of bipolar I disorder (Adults); 3. Adjunctive treatment of major depressive disorder (Adults); 4.Treatment of irritability associated with autistic disorder (Pediatric Patients [ages 6-17 years]). B. as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (Adults)."
Aripiprazole,129722-12-9,Aripiprazole,DB01238,irritability,,original,"A. as oral formulations for the: 1.Treatment of schizophrenia (Adults & Adolescents [ages 13-17]); 2. Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (Adults & Pediatric Patients [ages 10-17]), Maintenance treatment of bipolar I disorder (Adults); 3. Adjunctive treatment of major depressive disorder (Adults); 4.Treatment of irritability associated with autistic disorder (Pediatric Patients [ages 6-17 years]). B. as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (Adults)."
Aripiprazole,129722-12-9,Aripiprazole,DB01238,Gilles de la Tourette syndrome,doid:11119,repositioned,Treatment of Tourette's syndrome 
Arsenic trioxide,1327-53-3,Arsenic trioxide,DB01169,acute promyelocytic leukemia,doid:0060318,original,"For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression."
Arsenic trioxide,1327-53-3,Arsenic trioxide,DB01169,acute myeloid leukemia,doid:9119,repositioned,"Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7"
Arsenic trioxide,1327-53-3,Arsenic trioxide,DB01169,chronic lymphocytic leukemia,doid:1040,repositioned,Treatment of chronic lymphocytic leukemia
Arsenic trioxide,1327-53-3,Arsenic trioxide,DB01169,myeloid leukemia,doid:8692,repositioned,Treatment of chronic myeloid leukemia
Arsenic trioxide,1327-53-3,Arsenic trioxide,DB01169,liver cancer,doid:3571,repositioned,Treatment of liver cancer
Arsenic trioxide,1327-53-3,Arsenic trioxide,DB01169,malignant glioma,doid:3070,repositioned,Treatment of malignant glioma
Arsenic trioxide,1327-53-3,Arsenic trioxide,DB01169,multiple myeloma,doid:9538,repositioned,Treatment of multiple myeloma.
Arsenic trioxide,1327-53-3,Arsenic trioxide,DB01169,myelodysplastic syndrome,doid:0050908,repositioned,Treatment of myelodysplastic syndrome.
Ascorbic acid,50-81-7,Vitamin C,DB00126,**nutritional additive**,,original,A vitamin. An ingredient of approved multi-vitamins
Ascorbic acid,50-81-7,Vitamin C,DB00126,Charcot-Marie-Tooth disease,doid:10595,repositioned,Treatment of Charcot-Marie-Tooth disease type 1A.
Ascorbic acid,50-81-7,Vitamin C,DB00126,scurvy,doid:13724,repositioned,Treatment of scurvy 
Atomoxetine hydrochloride,82248-59-7,Atomoxetine,DB00289,attention deficit hyperactivity disorder,doid:1094,original,Treatment of Attention Deficit Hyperactivity Disorder.
Atomoxetine hydrochloride,82248-59-7,Atomoxetine,DB00289,Gilles de la Tourette syndrome,doid:11119,repositioned,Treatment of Tourette's Syndrome
Atovaquone,95233-18-4,Atovaquone,DB01117,pneumocystosis,doid:11339,original,For the acute oral treatment of mild to moderate Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole.
Atovaquone,95233-18-4,Atovaquone,DB01117,toxoplasmosis,doid:9965,repositioned,Primary prophylaxis of HIV-infected persons at high risk for developing Toxoplasma gondii encephalitis.
Azacitidine,320-67-2,Azacitidine,DB00928,myelodysplastic syndrome,doid:0050908,original,"Treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia and requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia."
Azacitidine,320-67-2,Azacitidine,DB00928,myeloid leukemia,doid:8692,repositioned,Treatment of acute myeloid leukemia
Azathioprine,446-86-6,Azathioprine,DB00993,rheumatoid arthritis,doid:7148,original,Azathioprine is  indicated for the management of active rheumatoid arthritis to reduce signs and symptoms.
Azathioprine,446-86-6,Azathioprine,DB00993,Transplant Rejection,,original,Azathioprine is indicated as an adjunct for the prevention of rejection in renal homotransplantation.
Azathioprine,446-86-6,Azathioprine,DB00993,graft vs host disease,,repositioned,Treatment of oral manifestations of graft-versus-host disease.
Aztreonam,78110-38-0,Aztreonam,DB00355,bacterial infectious disease,doid:104,original,"It is indicated for the treatment of the infections caused by various susceptible gram-negative microorganisms. See http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050580s040,050632s013lbl.pdf"
Aztreonam,78110-38-0,Aztreonam,DB00355,primary bacterial infectious disease,doid:0050338,original,It is indicated to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa.
Aztreonam,78110-38-0,Aztreonam,DB00355,bacterial infectious disease,doid:104,repositioned,Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.
Bacitracin,1405-87-4,Bacitracin,DB00626,bacterial infectious disease,doid:104,original,For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin susceptible organisms.
Bacitracin,1405-87-4,Bacitracin,DB00626,bacterial pneumonia,doid:874,original,The use of intramuscular bacitracin should be limited to the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug.
Bacitracin,1405-87-4,Bacitracin,DB00626,perinatal necrotizing enterocolitis,doid:8677,repositioned,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.
"Beclomethasone 17,21-diproprionate",5534-09-8,Beclomethasone dipropionate,DB00394,asthma,doid:2841,original,"Maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. It is also indicated for asthma patients who require systemic corticosteroid administration, where adding it may reduce or eliminate the need for the systemic corticosteroids."
"Beclomethasone 17,21-diproprionate",5534-09-8,Beclomethasone dipropionate,DB00394,rhinitis,doid:4483,original,Relief of the symptoms of seasonal or perennial rhinitis in those cases poorly responsive to conventional treatment. It is also indicated for the prevention of recurrence of nasal polyps following surgical removal.
"Beclomethasone 17,21-diproprionate",5534-09-8,Beclomethasone dipropionate,DB00394,graft vs host disease,,repositioned,For oral administration in the treatment of intestinal graft-versus-host disease.  
"Beclomethasone 17,21-diproprionate",5534-09-8,Beclomethasone dipropionate,DB00394,ulcerative colitis,doid:8577,repositioned,Treatment of pediatriac patients with ulcerative colitis
"Beclomethasone 17,21-diproprionate",5534-09-8,Beclomethasone dipropionate,DB00394,Crohn's disease,doid:8778,repositioned,Treatment of pediatric patients with Crohn disease.
Beractant,1088778-82-1,Beractant,DB06761,newborn respiratory distress syndrome,doid:12716,original,Prevention of Respiratory Distress Syndrome (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency.
Beractant,1088778-82-1,Beractant,DB06761,meconium aspiration syndrome,doid:11049,repositioned,"Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis."
Bethanidine sulfate,55-73-2,Bethanidine,DB00217,hypertension,doid:10763,original,Treatment of hypertension. 
Bethanidine sulfate,55-73-2,Bethanidine,DB00217,cardiac arrest,doid:0060319,repositioned,Prevention of recurrence of primary ventricular fibrillation.
Bevacizumab,216974-75-3,Bevacizumab,DB00112,glioblastoma multiforme,doid:3068,original,"Glioblastoma, as a single agent for patients with progressive disease following prior therapy."
Bevacizumab,216974-75-3,Bevacizumab,DB00112,colorectal cancer,doid:9256,original,"Treatment of: 1. Metastatic colorectal cancer, with intravenous 5-fluorouracil_based chemotherapy for first- or second-line treatment.  2. Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease. 3. Metastatic breast cancer, with paclitaxel for treatment of patients who have not received chemotherapy for metastatic HER2-negative breast cancer. 4. Metastatic renal cell carcinoma with interferon alfa"
Bevacizumab,216974-75-3,Bevacizumab,DB00112,non-small cell lung carcinoma,doid:3908,original,"Treatment of: 1. Metastatic colorectal cancer, with intravenous 5-fluorouracil_based chemotherapy for first- or second-line treatment.  2. Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease. 3. Metastatic breast cancer, with paclitaxel for treatment of patients who have not received chemotherapy for metastatic HER2-negative breast cancer. 4. Metastatic renal cell carcinoma with interferon alfa"
Bevacizumab,216974-75-3,Bevacizumab,DB00112,breast cancer,doid:1612,original,"Treatment of: 1. Metastatic colorectal cancer, with intravenous 5-fluorouracil_based chemotherapy for first- or second-line treatment.  2. Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease. 3. Metastatic breast cancer, with paclitaxel for treatment of patients who have not received chemotherapy for metastatic HER2-negative breast cancer. 4. Metastatic renal cell carcinoma with interferon alfa"
Bevacizumab,216974-75-3,Bevacizumab,DB00112,renal cell carcinoma,doid:4450,original,"Treatment of: 1. Metastatic colorectal cancer, with intravenous 5-fluorouracil_based chemotherapy for first- or second-line treatment.  2. Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease. 3. Metastatic breast cancer, with paclitaxel for treatment of patients who have not received chemotherapy for metastatic HER2-negative breast cancer. 4. Metastatic renal cell carcinoma with interferon alfa"
Bevacizumab,216974-75-3,Bevacizumab,DB00112,stomach cancer,doid:10534,repositioned,In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.
Bevacizumab,216974-75-3,Bevacizumab,DB00112,melanoma,doid:1909,repositioned,Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen
Bevacizumab,216974-75-3,Bevacizumab,DB00112,ovarian cancer,doid:2394,repositioned,Treatment of ovarian cancer
Bevacizumab,216974-75-3,Bevacizumab,DB00112,pancreatic cancer,doid:1793,repositioned,Treatment of pancreatic cancer
Bivalirudin,128270-60-0,Hirulog,DB02351,intermediate coronary syndrome,doid:8805,original,Use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty.
Bivalirudin,128270-60-0,Hirulog,DB02351,thrombocytopenia,doid:1588,repositioned,For use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome
Bleomycin sulfate,11056-06-7,Bleomycin,DB00290,squamous cell carcinoma,doid:1749,original,"Bleomycin has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous cell carcinoma from head and neck; Lymphomas (Hodgkin's and non-Hodgkin's); Testicular Carcinoma (embryonal cell, choriocarcinoma and teratocarcinoma)."
Bleomycin sulfate,11056-06-7,Bleomycin,DB00290,lymphoma,doid:0060058,original,"Bleomycin has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous cell carcinoma from head and neck; Lymphomas (Hodgkin's and non-Hodgkin's); Testicular Carcinoma (embryonal cell, choriocarcinoma and teratocarcinoma)."
Bleomycin sulfate,11056-06-7,Bleomycin,DB00290,testicular cancer,doid:2998,original,"Bleomycin has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous cell carcinoma from head and neck; Lymphomas (Hodgkin's and non-Hodgkin's); Testicular Carcinoma (embryonal cell, choriocarcinoma and teratocarcinoma)."
Bleomycin sulfate,11056-06-7,Bleomycin,DB00290,Malignant pleural effusion,,original,Treatment of malignant pleural effusion.
Bleomycin sulfate,11056-06-7,Bleomycin,DB00290,pancreatic cancer,doid:1793,repositioned,Treatment of pancreatic cancer.
Bosentan,147536-97-8,Bosentan,DB00559,pulmonary hypertension,doid:6432,original,"Treatment of pulmonary arterial hypertension (WHO Group I) in patients with WHO Class II - IV symptoms, to improve exercise ability and decrease the rate of clinical worsening "
Bosentan,147536-97-8,Bosentan,DB00559,idiopathic pulmonary fibrosis,doid:0050156,repositioned,Treatment of idiopathic pulmonary fibrosis
Botulinum toxin type A,93384-43-1,Botulinum Toxin Type A,DB00083,Upper limb spasticity,,original,1. Upper limb spasticity in adult patients. 2. Severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients.
Botulinum toxin type A,93384-43-1,Botulinum Toxin Type A,DB00083,blepharospasm,doid:529,original,Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above).
Botulinum toxin type A,93384-43-1,Botulinum Toxin Type A,DB00083,cervical dystonia,doid:0050840,original,Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.
Botulinum toxin type A,93384-43-1,Botulinum Toxin Type A,DB00083,strabismus,doid:540,original,Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above).
Botulinum toxin type A,93384-43-1,Botulinum Toxin Type A,DB00083,spastic cerebral palsy,doid:0050669,repositioned,Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.
Botulinum toxin type A,93384-43-1,Botulinum Toxin Type A,DB00083,jaw-winking syndrome,doid:560,repositioned,Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.
Brimonidine,59803-98-4,Brimonidine,DB00484,ocular hypertension,doid:9282,original,Indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Brimonidine,59803-98-4,Brimonidine,DB00484,open-angle glaucoma,doid:1067,original,Indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Brimonidine,59803-98-4,Brimonidine,DB00484,neuropathy,doid:870,repositioned,Treatment of anterior ischemic optic neuropathy.
Bupivacaine,2180-92-9,Bupivacaine,DB00297,**Analgesic**,,original,"Indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures."
Bupivacaine,2180-92-9,Bupivacaine,DB00297,postherpetic neuralgia,,repositioned,Relief of persistent pain asociated with postherpetic neuralgia
Busulfan,55-98-1,Busulfan,DB01008,chronic myeloid leukemia,doid:8552,original,Busulfan injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.  
Busulfan,55-98-1,Busulfan,DB01008,neoplastic meningitis,,repositioned,Intrathecal therapy for neoplastic meningitis
Busulfan,55-98-1,Busulfan,DB01008,brain cancer,doid:1319,repositioned,Treatment of primary brain malignancies.
Calcium carbonate,471-34-1 ,Calcium carbonate,DB06724,gastroesophageal reflux disease,doid:8534,original,Antacid
Calcium carbonate,471-34-1 ,Calcium carbonate,DB06724,hyperphosphatemia,doid:0050459,repositioned,Treatment of hyperphosphatemia in patients with end stage renal disease.
Calfactant,183325-78-2,Calfactant,DB06415,newborn respiratory distress syndrome,doid:12716,original,Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.
Calfactant,183325-78-2,Calfactant,DB06415,adult respiratory distress syndrome,doid:11394,repositioned,Acute respiratory distress syndrome
Canakinumab,914613-48-2,Canakinumab,DB06168,Familial Cold Autoinflammatory Syndrome,,original,"Treatment of cryopyrin-associated periodic syndromes, in adults and children 4 years of age and older including: Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome."
Canakinumab,914613-48-2,Canakinumab,DB06168,Muckle-Wells syndrome,doid:0050854,original,"Treatment of cryopyrin-associated periodic syndromes, in adults and children 4 years of age and older including: Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome."
Canakinumab,914613-48-2,Canakinumab,DB06168,juvenile rheumatoid arthritis,doid:676,repositioned,Treatment of systemic onset juvenile idiopathic arthritis
Capsaicin,404-86-4,Capsaicin,DB06774,postherpetic neuralgia,,original,Management of neuropathic pain associated with postherpetic neuralgia
Capsaicin,404-86-4,Capsaicin,DB06774,erythromelalgia,doid:9240,repositioned,Treatment of erythromelalgia
Capsaicin,404-86-4,Capsaicin,DB06774,intermetatarsal neuroma,,repositioned,Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis
Capsaicin,404-86-4,Capsaicin,DB06774,neuropathy,doid:870,repositioned,Treatment of painful HIV-associated neuropathy
Ceftriaxone sodium,73384-59-5,Ceftriaxone,DB01212,bacterial infectious disease,doid:104,original,Treatment of infections when caused by susceptible organisms. See details at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17632#nlm34067-9
Ceftriaxone sodium,73384-59-5,Ceftriaxone,DB01212,amyotrophic lateral sclerosis,doid:332,repositioned,Treatment of amyotrophic lateral sclerosis
Celecoxib,169590-42-5,Celecoxib,DB00482,osteoarthritis,doid:8398,original,Osteoarthritis and adult rheumatoid arthritis 
Celecoxib,169590-42-5,Celecoxib,DB00482,rheumatoid arthritis,doid:7148,original,Osteoarthritis and adult rheumatoid arthritis 
Celecoxib,169590-42-5,Celecoxib,DB00482,familial adenomatous polyposis,doid:0050424,repositioned,Familial adenomatous polyposis
Celecoxib,169590-42-5,Celecoxib,DB00482,breast cancer,doid:1612,repositioned,breast cancer
Celecoxib,169590-42-5,Celecoxib,DB00482,colon cancer,doid:219,repositioned,colon cancer
Cetuximab,205923-56-4,Cetuximab,DB00002,colorectal cancer,doid:9256,original,"As a single agent, EGFR-expressing metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-based regimens or in patients who are intolerant to irinotecan-based regimens.; _In combination with irinotecan, EGFR-expressing metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy."
Cetuximab,205923-56-4,Cetuximab,DB00002,squamous cell carcinoma,doid:1749,original,Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy;_ Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy.
Cetuximab,205923-56-4,Cetuximab,DB00002,pancreatic cancer,doid:1793,repositioned,Treatment of pancreatic cancer
Chlorhexidine gluconate mouthrinse,55-56-1,Chlorhexidine,DB00878,gingivitis,doid:3087,original,"For use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing."
Chlorhexidine gluconate mouthrinse,55-56-1,Chlorhexidine,DB00878,Oral mucositis,,repositioned,For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.
Chlorpromazine,50-53-3,Chlorpromazine,DB00477,**Anti-emetic**,,original,Anti-emetic/antihistamine
Chlorpromazine,50-53-3,Chlorpromazine,DB00477,**Tranquilizer**,,repositioned,Non-sedating tranquillizer
Ciprofloxacin pulmosphere©,85712-33-1,Ciprofloxacin,DB00537,bronchiectasis,doid:9563,repositioned,Management of bronchiectasis
Ciprofloxacin pulmosphere©,85712-33-1,Ciprofloxacin,DB00537,primary bacterial infectious disease,doid:0050338,repositioned,Management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients
Cladribine,4291-63-8,Cladribine,DB00242,hairy cell leukemia,doid:285,original,Treatment of hairy cell leukemia.
Cladribine,4291-63-8,Cladribine,DB00242,acute myeloid leukemia,doid:9119,repositioned,Treatment of acute myeloid leukemia.
Cladribine,4291-63-8,Cladribine,DB00242,chronic lymphocytic leukemia,doid:1040,repositioned,Treatment of chronic lymphocytic leukemia.
Cladribine,4291-63-8,Cladribine,DB00242,non-Hodgkin lymphoma,doid:0060060,repositioned,Treatment of non-Hodgkin's lymphoma.
Clindamycin,18323-44-9,Clindamycin,DB01190,bacterial infectious disease,doid:104,original,"Treatment of serious infections caused by susceptible anaerobic bacteria, as well as streptococci, pneumococci and staphlococci. See details at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=15339#nlm34067-9"
Clindamycin,18323-44-9,Clindamycin,DB01190,pneumocystosis,doid:11339,repositioned,Prevention of Pneumocystis carinii pneumonia in AIDS patients.
Clindamycin,18323-44-9,Clindamycin,DB01190,sarcoidosis,doid:11335,repositioned,Treatment of sarcoidosis
Clofarabine,123318-82-1,Clofarabine,DB00631,lymphoblastic leukemia,doid:1037,original,Treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.
Clofarabine,123318-82-1,Clofarabine,DB00631,acute myeloid leukemia,doid:9119,repositioned,Treatment of acute myelogenous leukemia
Clonazepam,1622-61-3,Clonazepam,DB01068,Lennox-Gastaut syndrome,doid:0050561,original,"1. Seizure Disorders: Useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. It may be useful in patients with absence seizures (petit mal) who have failed to respond to succinimides. 2. Panic Disorder: Treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. "
Clonazepam,1622-61-3,Clonazepam,DB01068,panic disorder,doid:594,original,"1. Seizure Disorders: Useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. It may be useful in patients with absence seizures (petit mal) who have failed to respond to succinimides. 2. Panic Disorder: Treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. "
Clonazepam,1622-61-3,Clonazepam,DB01068,hyperekplexia,doid:0060695,repositioned,Treatment of hyperekplexia (startle disease).
Clonazepam Intranasal Spray,1622-61-3,Clonazepam,DB01068,epilepsy,doid:1826,repositioned,Treatment of recurrent acute repetitive seizures
Clotrimazole,23593-75-1,Clotrimazole,DB00257,oral candidiasis,doid:14262,original,Clotrimazole Troches (clotrimazole lozenges) are indicated for the local treatment of oropharyngeal candidiasis
Clotrimazole,23593-75-1,Clotrimazole,DB00257,candidiasis,doid:1508,original,For the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur.
Clotrimazole,23593-75-1,Clotrimazole,DB00257,pityriasis versicolor,doid:9060,original,For the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur.
Clotrimazole,23593-75-1,Clotrimazole,DB00257,pouchitis,,repositioned,Topical treatment of children and adults with pouchitis
Clotrimazole,23593-75-1,Clotrimazole,DB00257,Huntington's disease,doid:12858,repositioned,Treatment of Huntington's disease
Clotrimazole,23593-75-1,Clotrimazole,DB00257,sickle cell anemia,doid:10923,repositioned,Treatment of sickle cell disease.
Coagulation Factor VIIa (Recombinant),102786-61-8,Coagulation factor VIIa Recombinant Human,DB00036,inherited blood coagulation disease,doid:2214,original,Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.
Coagulation Factor VIIa (Recombinant),102786-61-8,Coagulation factor VIIa Recombinant Human,DB00036,blood coagulation disease,doid:1247,original,Prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia.
Coagulation Factor VIIa (Recombinant),102786-61-8,Coagulation factor VIIa Recombinant Human,DB00036,Glanzmann's thrombasthenia,doid:2219,repositioned,Prevention of bleeding episodes in Glanzmann's thrombasthenia 
Coagulation Factor VIIa (Recombinant),102786-61-8,Coagulation factor VIIa Recombinant Human,DB00036,intracranial hemorrhage,,repositioned,Treatment of bleeding in patients experiencing intracranial hemorrhage.
Colchicine,64-86-8,Colchicine,DB01394,gout,doid:13189,original,It is indicated for gout flares.
Colchicine,64-86-8,Colchicine,DB01394,brucellosis,doid:11077,original,Treatment of Familial Mediterranean fever in adults and children 4 years or older.
Colchicine,64-86-8,Colchicine,DB01394,Behcet's disease,doid:13241,repositioned,Treatment of Behcet's Syndrome
Collagenase (lyophilized) for injection,9001-12-1,Collagenase clostridium histolyticum,DB00048,**debriding**,,original,Collagenase Santyl© Ointment is indicated for debriding chronic dermal ulcers and severely burned areas.
Collagenase (lyophilized) for injection,9001-12-1,Collagenase clostridium histolyticum,DB00048,Peyronie's disease,doid:8616,repositioned,Treatment of Peyronie's disease. 
Cyclosporine,59865-13-3,Cyclosporine,DB00091,rheumatoid arthritis,doid:7148,original,"1. Treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. It can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. 2 It is also indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (eg., PUVA, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated, or cannot be tolerated."
Cyclosporine,59865-13-3,Cyclosporine,DB00091,psoriasis,doid:8893,original,"1. Treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. It can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. 2 It is also indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (eg., PUVA, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated, or cannot be tolerated."
Cyclosporine,59865-13-3,Cyclosporine,DB00091,Transplant Rejection,,original,"Prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. It is always to be used with adrenal corticosteroids. The drug may also be used in the treatment of chronic rejection in patients previously treated with other immunosuppressive agents.   "
Cyclosporine,59865-13-3,Cyclosporine,DB00091,Transplant Rejection,,repositioned,Prevention of corneal graft rejection
Cyclosporine,59865-13-3,Cyclosporine,DB00091,amyotrophic lateral sclerosis,doid:332,repositioned,Treatment of amyotrophic lateral sclerosis and its variants
Cyclosporine,59865-13-3,Cyclosporine,DB00091,herpes simplex virus keratitis,doid:0080158,repositioned,Treatment of herpes simplex virus stromal keratitis
Cyclosporine,59865-13-3,Cyclosporine,DB00091,keratoconjunctivitis,doid:9368,repositioned,Treatment of vernal keratoconjunctivitis
Cyclosporine 2% ophthalmic ointment,59865-13-3,Cyclosporine,DB00091,keratoconjunctivitis sicca,doid:12895,original,Increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with deratoconjunctivites sicca.
Cyclosporine 2% ophthalmic ointment,59865-13-3,Cyclosporine,DB00091,keratoconjunctivitis sicca,doid:12895,repositioned,Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.
Cysteamine hydrochloride,60-23-1,Cysteamine,DB00847,Fanconi syndrome,doid:1062,original,Treatment of nephropathic cystinosis in adults and children. 
Cysteamine hydrochloride,60-23-1,Cysteamine,DB00847,Huntington's disease,doid:12858,repositioned,Treatment of Huntington's disease
Cysteamine hydrochloride,60-23-1,Cysteamine,DB00847,cystinosis,doid:1064,repositioned,Treatment of corneal cystine crystal accumulation in cystinosis patients.
Cysteamine hydrochloride,60-23-1,Cysteamine,DB00847,neuronal ceroid lipofuscinosis,doid:14503,repositioned,Treatment of neuronal ceroid lipofuscinoses (Batten disease)
Cytarabine,147-94-4,Cytarabine,DB00987,myeloid leukemia,doid:8692,original,Cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. 
Cytarabine,147-94-4,Cytarabine,DB00987,adult acute lymphocytic leukemia,doid:5604,original,Cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. 
Cytarabine,147-94-4,Cytarabine,DB00987,lymphomatous meningitis,,original,Intrathecal treatment of lymphomatous meningitis. 
Cytarabine,147-94-4,Cytarabine,DB00987,malignant glioma,doid:3070,repositioned,Treatment of gliomas
Cytomegalovirus immunoglobulin intravenous (human),,,,CMV,,original,"#1) Attenuation of primary CMV disease associated with kidney transplant recipients who are seronegative for CMV and who receive a kidney from a CMV seropositve donor; #2)  Prophylaxis of CMV disease associated transplantation of kidney (all other), lung,"
Cytomegalovirus immunoglobulin intravenous (human),,,,CMV,,repositioned,For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.
Dapoxetine,119356-77-3,Dapoxetine,DB04884,**Analgesic**,,original,Analgesia and depression
Dapoxetine,119356-77-3,Dapoxetine,DB04884,mental depression,doid:1596,original,Analgesia and depression
Dapoxetine,119356-77-3,Dapoxetine,DB04884,premature ejaculation,doid:13709,repositioned,Premature ejaculation
Dapsone,80-08-0,Dapsone,DB00250,acne,doid:6543,original,Aczone (dapsone) Gel is indicated for the topical treatment of acne vulgaris.
Dapsone,80-08-0,Dapsone,DB00250,dermatitis herpetiformis,doid:8505,original,To control the dermatologic symptoms of Dermatitis herpetiformis. Dapsone is used alone or in combination with other anti-leprosy drugs for leprosy. 
Dapsone,80-08-0,Dapsone,DB00250,pneumocystosis,doid:11339,repositioned,For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.
Dapsone,80-08-0,Dapsone,DB00250,toxoplasmosis,doid:9965,repositioned,Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.
Daunorubicin liposomal,20830-81-3,Daunorubicin,DB00694,Kaposi's sarcoma,doid:8632,original,"DaunoXome (daunorubicin citrate)  injection, lipid complex  is indicated as a first line cytotoxic therapy for advanced HIV-associated Kaposi's sarcoma. "
Daunorubicin liposomal,20830-81-3,Daunorubicin,DB00694,myeloid leukemia,doid:8692,original,"Daunorubicin hydrochloride in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults"
Daunorubicin liposomal,20830-81-3,Daunorubicin,DB00694,acute myeloid leukemia,doid:9119,repositioned,Treatment of acute myeloid leukemia
Decitabine,2353-33-5,Decitabine,DB01262,myelodysplastic syndrome,doid:0050908,original,"For treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia."
Decitabine,2353-33-5,Decitabine,DB01262,leukemia,doid:1240,repositioned,Treatment of acute leukemia.
Decitabine,2353-33-5,Decitabine,DB01262,myeloid leukemia,doid:8692,repositioned,Treatment of acute myeloid leukemia
Decitabine,2353-33-5,Decitabine,DB01262,chronic myeloid leukemia,doid:8552,repositioned,Treatment of chronic myelogenous leukemia.  
Decitabine,2353-33-5,Decitabine,DB01262,sickle cell anemia,doid:10923,repositioned,Treatment of sickle cell anemia
Dexamethasone intravitreal implant,50-02-2,Dexamethasone,DB01234,panuveitis,doid:12030,repositioned,"Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis. "
Dexamethasone phosphate,50-02-2,Dexamethasone,DB01234,conjunctivitis,doid:6195,original,"DEXAMETHASONE SODIUM PHOSPHATE solution/ drop is indicated for the treatment of the following conditions: 1. Ophthalmic - Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal bums, or penetration of foreign bodies. 2. Otic - Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation."
Dexamethasone phosphate,50-02-2,Dexamethasone,DB01234,rosacea,doid:8881,original,"DEXAMETHASONE SODIUM PHOSPHATE solution/ drop is indicated for the treatment of the following conditions: 1. Ophthalmic - Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal bums, or penetration of foreign bodies. 2. Otic - Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation."
Dexamethasone phosphate,50-02-2,Dexamethasone,DB01234,punctate epithelial keratoconjunctivitis,doid:12197,original,"DEXAMETHASONE SODIUM PHOSPHATE solution/ drop is indicated for the treatment of the following conditions: 1. Ophthalmic - Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal bums, or penetration of foreign bodies. 2. Otic - Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation."
Dexamethasone phosphate,50-02-2,Dexamethasone,DB01234,herpes zoster keratitis,,original,"DEXAMETHASONE SODIUM PHOSPHATE solution/ drop is indicated for the treatment of the following conditions: 1. Ophthalmic - Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal bums, or penetration of foreign bodies. 2. Otic - Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation."
Dexamethasone phosphate,50-02-2,Dexamethasone,DB01234,uveitis,doid:13141,original,"DEXAMETHASONE SODIUM PHOSPHATE solution/ drop is indicated for the treatment of the following conditions: 1. Ophthalmic - Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal bums, or penetration of foreign bodies. 2. Otic - Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation."
Dexamethasone phosphate,50-02-2,Dexamethasone,DB01234,iridocyclitis,doid:9383,original,"DEXAMETHASONE SODIUM PHOSPHATE solution/ drop is indicated for the treatment of the following conditions: 1. Ophthalmic - Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal bums, or penetration of foreign bodies. 2. Otic - Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation."
Dexamethasone phosphate,50-02-2,Dexamethasone,DB01234,otitis externa,doid:9463,original,"DEXAMETHASONE SODIUM PHOSPHATE solution/ drop is indicated for the treatment of the following conditions: 1. Ophthalmic - Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal bums, or penetration of foreign bodies. 2. Otic - Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation."
Dexamethasone phosphate,50-02-2,Dexamethasone,DB01234,Transplant Rejection,,repositioned,Treatment of corneal graft rejection.
Dextran 1,9004-54-0,Dextran,DB09255,Anaphylaxis,,original,Dextran 1 is used to prevent severe anaphylactic reactions to infusions of dextran. 
Dextran 1,9004-54-0,Dextran,DB09255,cystic fibrosis,doid:1485,repositioned,Treatment of cystic fibrosis 
Dextran 70,9004-54-0,Dextran,DB09255,recurrent corneal erosion,doid:11541,repositioned,Treatment of recurrent corneal erosion unresponsive to conventional therapy.
Difluprednate,23674-86-4,Difluprednate,DB06781,panuveitis,doid:12030,original,"Difluprednate ophthalmic emulsion 0.05%, a topical corticosteroid, is indicated for the treatment of inflammation and pain associated with ocular surgery. "
Difluprednate,23674-86-4,Difluprednate,DB06781,uveitis,doid:13141,repositioned,Treatment of endogenous and traumatic anterior uveitis and panuveitis. 
Digitoxin,71-63-6,Digitoxin,DB01396,cardiac arrhythmia,,original,Digitoxin is a cardiac glycoside with positive inotropic activity. It has actions similar to those of digoxin and is used in the management of some cardiac arrhythmias and in heart failure. 
Digitoxin,71-63-6,Digitoxin,DB01396,cystic fibrosis,doid:1485,repositioned,Treatment of cystic fibrosis
Digitoxin,71-63-6,Digitoxin,DB01396,ovarian cancer,doid:2394,repositioned,Treatment of ovarian cancer
Digitoxin,71-63-6,Digitoxin,DB01396,sarcoma,doid:1115,repositioned,Treatment of soft tissue sarcomas
Dimethyl sulfoxide,67-68-5,Dimethyl sulfoxide,DB01093,interstitial cystitis,doid:13949,original,Symptomatic relief of patients with interstitial cystitis.
Dimethyl sulfoxide,67-68-5,Dimethyl sulfoxide,DB01093,tuberculosis,doid:399,repositioned,For use in combination with antimicrobial drugs for the treatment of drug resistant tuberculosis
Dimethyl sulfoxide,67-68-5,Dimethyl sulfoxide,DB01093,**Injury Prevention**,,repositioned,Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs. 
Dimethyl sulfoxide,67-68-5,Dimethyl sulfoxide,DB01093,systemic scleroderma,doid:418,repositioned,Treatment of cutaneous manifestations of scleroderma.
Dimethyl sulfoxide,67-68-5,Dimethyl sulfoxide,DB01093,intracranial hypertension,doid:9428,repositioned,"Treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available."
Doripenem,148016-81-3,Doripenem,DB06211,bacterial infectious disease,doid:104,original,"Treatment of the following infections caused by designated susceptible bacteria: Complicated intra-abdominal infections; Complicated urinary tract infections, including pyelonephritis. See details at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8708#nlm34067-9"
Doripenem,148016-81-3,Doripenem,DB06211,bacterial infectious disease,doid:104,repositioned,Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.
Doxorubicin,23214-92-8,Doxorubicin,DB00997,breast cancer,doid:1612,original,"1. Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as  breast carcinoma,  transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, 2. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer."
Doxorubicin,23214-92-8,Doxorubicin,DB00997,bladder urothelial carcinoma,doid:4006,original,"1. Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as  breast carcinoma,  transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, 2. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer."
Doxorubicin,23214-92-8,Doxorubicin,DB00997,thyroid cancer,doid:1781,original,"1. Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as  breast carcinoma,  transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, 2. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer."
Doxorubicin,23214-92-8,Doxorubicin,DB00997,stomach cancer,doid:10534,original,"1. Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as  breast carcinoma,  transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, 2. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer."
Doxorubicin,23214-92-8,Doxorubicin,DB00997,lymphoblastic leukemia,doid:1037,original,"Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas,  ovarian carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types."
Doxorubicin,23214-92-8,Doxorubicin,DB00997,acute myeloid leukemia,doid:9119,original,"Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas,  ovarian carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types."
Doxorubicin,23214-92-8,Doxorubicin,DB00997,nephroblastoma,doid:2154,original,"Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas,  ovarian carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types."
Doxorubicin,23214-92-8,Doxorubicin,DB00997,neuroblastoma,doid:769,original,"Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas,  ovarian carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types."
Doxorubicin,23214-92-8,Doxorubicin,DB00997,sarcoma,doid:1115,original,"Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas,  ovarian carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types."
Doxorubicin,23214-92-8,Doxorubicin,DB00997,ovarian cancer,doid:2394,original,"Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas,  ovarian carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types."
Doxorubicin,23214-92-8,Doxorubicin,DB00997,Hodgkin's lymphoma,doid:8567,original,"Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas,  ovarian carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types."
Doxorubicin,23214-92-8,Doxorubicin,DB00997,lymphoma,doid:0060058,original,"Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas,  ovarian carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types."
Doxorubicin,23214-92-8,Doxorubicin,DB00997,bronchus carcinoma,doid:3904,original,"Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas,  ovarian carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types."
Doxorubicin,23214-92-8,Doxorubicin,DB00997,hepatocellular carcinoma,doid:684,repositioned,Treatment of hepatocellular carcinoma.
Doxorubicin HCl with pluronic L-61 and pluronic F-127,23214-92-8,Doxorubicin,DB00997,esophageal carcinoma,doid:1107,repositioned,Treatment of esophageal carcinoma.
Doxorubicin HCl with pluronic L-61 and pluronic F-127,23214-92-8,Doxorubicin,DB00997,stomach cancer,doid:10534,repositioned,Treatment of gastric cancer.
Duloxetine,136434-34-9,Duloxetine,DB00476,mental depression,doid:1596,original,Depression
Duloxetine,136434-34-9,Duloxetine,DB00476,female stress incontinence,doid:724,repositioned,Stress urinary incontinence
Eculizumab,219685-50-4,Eculizumab,DB01257,hemoglobinuria,doid:582,original,Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis.
Eculizumab,219685-50-4,Eculizumab,DB01257,glomerular nephropathy,,repositioned,Idiopathic membranous glomerular nephropathy
Eculizumab,219685-50-4,Eculizumab,DB01257,hemolytic-uremic syndrome,doid:12554,repositioned,Treatment of atypical hemolytic uremic syndrome.
Eculizumab,219685-50-4,Eculizumab,DB01257,dermatomyositis,doid:10223,repositioned,Treatment of dermatomyositis.
Eflornithine HCl,70052-12-9,Eflornithine,DB06243,sleeping sickness,doid:10112,original,"Treatment of African trypanosomiasis (sleeping sickness), including the West African form (Trypanosoma brucei gambiense)."
Eflornithine HCl,70052-12-9,Eflornithine,DB06243,unwanted facial hair,,original,VANIQA (Eflurnithine HCl) cream is indicated for the reduction of unwanted facial hair in women.
Eflornithine HCl,70052-12-9,Eflornithine,DB06243,pneumocystosis,doid:11339,repositioned,Treatment of Pneumocystis carinii pneumonia in AIDS patients.
Eflornithine HCl,70052-12-9,Eflornithine,DB06243,grade III astrocytoma,doid:3078,repositioned,Treatment of anaplastic glioma.
Epoetin alpha,113427-24-0,Erythropoietin,DB00016,anemia,doid:2355,original,"Treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis. It is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or hemoglobin determinations) and to decrease the need for transfusions in these patients."
Epoetin alpha,113427-24-0,Erythropoietin,DB00016,anemia,doid:2355,repositioned,Treatment of anemia of prematurity in preterm infants.
Epoetin alpha,113427-24-0,Erythropoietin,DB00016,myelodysplastic syndrome,doid:0050908,repositioned,Treatment of myelodysplastic syndrome.
Epoprostenol,35121-78-9,Epoprostenol,DB01240,pulmonary hypertension,doid:6432,original,Long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Epoprostenol,35121-78-9,Epoprostenol,DB01240,**anti-coagualtion**,,repositioned,Replacement of heparin in patients requiring hemodialysis and who are at increased risk of hemorrhage.
Erlotinib Hydrochloride,183321-74-6,Erlotinib,DB00530,pancreatic cancer,doid:1793,original,"First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine."
Erlotinib Hydrochloride,183321-74-6,Erlotinib,DB00530,non-small cell lung carcinoma,doid:3908,original,Treatment of locally advanced or metastatic non-small cell lung cancer  after failure of at least one prior chemotherapy regimen.
Erlotinib Hydrochloride,183321-74-6,Erlotinib,DB00530,malignant glioma,doid:3070,repositioned,Treatment of malignant gliomas
Estradiol Gel,50-28-2,Estradiol,DB00783,Vasomotor symptoms,,original,Treatment of moderate to severe vasomotor symptoms associated with menopause.
Estradiol Gel,50-28-2,Estradiol,DB00783,Turner syndrome,doid:3491,repositioned,Estrogen replacement therapy in females with Turner syndrome
Etanercept,185243-69-0,Etanercept,DB00005,rheumatoid arthritis,doid:7148,original,"1. Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. 2. Reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. 3. Reducing signs and symptoms in patients with active ankylosing spondylitis. 4. Treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy."
Etanercept,185243-69-0,Etanercept,DB00005,psoriatic arthritis,doid:9008,original,"1. Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. 2. Reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. 3. Reducing signs and symptoms in patients with active ankylosing spondylitis. 4. Treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy."
Etanercept,185243-69-0,Etanercept,DB00005,ankylosing spondylitis,doid:7147,original,"1. Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. 2. Reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. 3. Reducing signs and symptoms in patients with active ankylosing spondylitis. 4. Treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy."
Etanercept,185243-69-0,Etanercept,DB00005,psoriasis,doid:8893,original,"1. Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. 2. Reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. 3. Reducing signs and symptoms in patients with active ankylosing spondylitis. 4. Treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy."
Etanercept,185243-69-0,Etanercept,DB00005,Wegener's granulomatosis,doid:12132,repositioned,Treatment of Wegener's granulomatosis.  
Ethinyl Estradiol,57-63-6,Ethinyl Estradiol,DB00977,**estrogen replacment**,,original,A synthetic oestrogen with actions similar to those of estradiol. It is frequently used as the oestrogenic component of combined oral contraceptive preparations
Ethinyl Estradiol,57-63-6,Ethinyl Estradiol,DB00977,Turner syndrome,doid:3491,repositioned,Treatment of Turner's syndrome.
Etidronate disodium,7414-83-7,Etidronic acid,DB01077,mammary Paget's disease,doid:3443,original,Etidronate disodium is indicated for the treatment of symptomatic Paget_s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. 
Etidronate disodium,7414-83-7,Etidronic acid,DB01077,myositis ossificans,doid:668,original,Etidronate disodium is indicated for the treatment of symptomatic Paget_s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. 
Etidronate disodium,7414-83-7,Etidronic acid,DB01077,hypercalcemia,doid:12678,original,Treatment of hypercalcemia in late-stage cancer patients.
Etidronate disodium,7414-83-7,Etidronic acid,DB01077,bone disease,doid:0080001,repositioned,Prevention of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.
Everolimus,159351-69-6,Everolimus,DB01590,Transplant Rejection,,original,Prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant. 
Everolimus,159351-69-6,Everolimus,DB01590,renal cell carcinoma,doid:4450,original,Treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.
Everolimus,159351-69-6,Everolimus,DB01590,neuroendocrine tumor,doid:169,repositioned,Treatment of gastroenteropancreatic neuroendocrine tumors
Everolimus,159351-69-6,Everolimus,DB01590,tuberous sclerosis,doid:13515,repositioned,"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"
Filgrastim,143011-72-7,Filgrastim,DB00099,neutropenia,doid:1227,original,Decreasing the incidence of infection_ as manifested by febrile neutropenia_ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
Filgrastim,143011-72-7,Filgrastim,DB00099,,,original,Mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.
Filgrastim,143011-72-7,Filgrastim,DB00099,neutropenia,doid:1227,original,Reducing the duration of neutropenia and neutropenia-related clinical sequelae_ eg_ febrile neutropenia_ in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation.
Filgrastim,143011-72-7,Filgrastim,DB00099,myeloid leukemia,doid:8692,original,"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia."
Filgrastim,143011-72-7,Filgrastim,DB00099,myelodysplastic syndrome,doid:0050908,repositioned,Treatment of myelodysplastic syndrome.
Filgrastim,143011-72-7,Filgrastim,DB00099,CMV,,repositioned,"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir."
Finasteride,98319-26-7,Finasteride,DB01216,prostatic adenoma,doid:2883,original,Benign prostatic hyperplasia
Finasteride,98319-26-7,Finasteride,DB01216,hair loss,,repositioned,Hair loss
Floxuridine,50-91-9,Floxuridine,DB00322,gastrointestinal system cancer,doid:3119,original,"Effective in the palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means. "
Floxuridine,50-91-9,Floxuridine,DB00322,stomach cancer,doid:10534,repositioned,Intraperitoneal treatment of gastric cancer. 
Fludarabine phosphate,75607-67-9,Fludarabine,DB01073,chronic lymphocytic leukemia,doid:1040,original,Fludara (Fludarabine Phosphate Injection) is indicated for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. 
Fludarabine phosphate,75607-67-9,Fludarabine,DB01073,non-Hodgkin lymphoma,doid:0060060,repositioned,Treatment and management of patients with non-Hodgkins lymphoma.
Fluorouracil,51-21-8,Fluorouracil,DB00544,colon cancer,doid:219,original,"Effective in the palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas."
Fluorouracil,51-21-8,Fluorouracil,DB00544,rectum cancer,doid:1993,original,"Effective in the palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas."
Fluorouracil,51-21-8,Fluorouracil,DB00544,breast cancer,doid:1612,original,"Effective in the palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas."
Fluorouracil,51-21-8,Fluorouracil,DB00544,stomach cancer,doid:10534,original,"Effective in the palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas."
Fluorouracil,51-21-8,Fluorouracil,DB00544,pancreatic cancer,doid:1793,original,"Effective in the palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas."
Fluorouracil,51-21-8,Fluorouracil,DB00544,actinic keratosis,doid:8866,original,"Recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. "
Fluorouracil,51-21-8,Fluorouracil,DB00544,basal cell carcinoma,doid:2513,original,"Recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. "
Fluorouracil,51-21-8,Fluorouracil,DB00544,esophageal cancer,doid:5041,repositioned,"For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma."
Fluorouracil,51-21-8,Fluorouracil,DB00544,glioblastoma multiforme,doid:3068,repositioned,Treatment of glioblastoma multiforme.
Fluoxetine,54910-89-3,Fluoxetine,DB00472,major depressive disorder,doid:1470,original,"Treatment of Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia Nervosa, Panic Disorder. "
Fluoxetine,54910-89-3,Fluoxetine,DB00472,obsessive-compulsive disorder,doid:10933,original,"Treatment of Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia Nervosa, Panic Disorder. "
Fluoxetine,54910-89-3,Fluoxetine,DB00472,bulimia nervosa,doid:12129,original,"Treatment of Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia Nervosa, Panic Disorder. "
Fluoxetine,54910-89-3,Fluoxetine,DB00472,panic disorder,doid:594,original,"Treatment of Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia Nervosa, Panic Disorder. "
Fluoxetine,54910-89-3,Fluoxetine,DB00472,premenstrual tension,doid:727,original,Treatment of premenstrual dysphoric disorder.
Fluoxetine,54910-89-3,Fluoxetine,DB00472,body dysmorphic disorder,doid:0060163,repositioned,Treatment of body dysmorphic disorder in children and adolescents
Gabapentin,60142-96-3,Gabapentin,DB00996,postherpetic neuralgia,,original,Indicated for the management of postherpetic neuralgia in adults. It is also indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. As adjunctive therapy in the treatment of partial seizures in pediatric patients age 3_ 12 years.
Gabapentin,60142-96-3,Gabapentin,DB00996,epilepsy,doid:1826,original,Indicated for the management of postherpetic neuralgia in adults. It is also indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. As adjunctive therapy in the treatment of partial seizures in pediatric patients age 3_ 12 years.
Gabapentin,60142-96-3,Gabapentin,DB00996,amyotrophic lateral sclerosis,doid:332,repositioned,Treatment of amyotrophic lateral sclerosis.
Galantamine,357-70-0,Galantamine,DB00674,postpoliomyelitis syndrome,doid:4952,original,"Polio, paralysis and anaesthesia"
Galantamine,357-70-0,Galantamine,DB00674,Alzheimer's disease,doid:10652,repositioned,Alzheimer_s disease
Glatiramer acetate for injection,147245-92-9,Glatiramer Acetate,DB05259,multiple sclerosis,doid:2377,original,For reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
Glatiramer acetate for injection,147245-92-9,Glatiramer Acetate,DB05259,amyotrophic lateral sclerosis,doid:332,repositioned,Treatment of amyothrophic lateral sclerosis (ALS).
Glycopyrrolate ,596-51-0,Glycopyrronium,DB00986,peptic ulcer disease,doid:750,original,For use as adjunctive therapy in the treatment of peptic ulcer.
Glycopyrrolate ,596-51-0,Glycopyrronium,DB00986,pathologic drooling,,repositioned,Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients
Guanethidine monosulfate,645-43-2,Guanethidine,DB01170,hypertension,doid:10763,original,"Treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension, including that secondary to pyelonephritis, renal amyloidosis, and renal artery stenosis."
Guanethidine monosulfate,645-43-2,Guanethidine,DB01170,reflex sympathetic dystrophy,doid:1811,repositioned,Treatment of moderate to severe reflex sympathetic dystrophy and causalgia.
Guanfacine,29110-47-2,Guanfacine,DB01018,attention deficit hyperactivity disorder,doid:1094,original,"Guanfacine tablet, extended release  is  indicated for the treatment of Attention Deficit Hyperactivity Disorder."
Guanfacine,29110-47-2,Guanfacine,DB01018,hypertension,doid:10763,original,Guanfacine tablets are indicated in the management of hypertension. 
Guanfacine,29110-47-2,Guanfacine,DB01018,fragile X syndrome,doid:14261,repositioned,Treatment of fragile X syndrome.
Heme arginate,100438-92-4,,,porphyria,doid:13268,original,Amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women.
Heme arginate,100438-92-4,,,myelodysplastic syndrome,doid:0050908,repositioned,Treatment of myelodysplastic syndromes.
Heparin,9005-49-6,Enoxaparin,DB01225,vein disease,doid:866,original,"Heparin Sodium Injection is indicated for:1. Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension;2.Low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; 3. Prophylaxis and treatment of pulmonary embolism; 4. Atrial fibrillation with embolization; 5. Diagnosis and treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); 6. Prevention of clotting in arterial and cardiac surgery; 7. Prophylaxis and treatment of peripheral arterial embolism. 8. Heparin may also be employed as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes."
Heparin,9005-49-6,Enoxaparin,DB01225,pulmonary embolism,doid:9477,original,"Heparin Sodium Injection is indicated for:1. Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension;2.Low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; 3. Prophylaxis and treatment of pulmonary embolism; 4. Atrial fibrillation with embolization; 5. Diagnosis and treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); 6. Prevention of clotting in arterial and cardiac surgery; 7. Prophylaxis and treatment of peripheral arterial embolism. 8. Heparin may also be employed as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes."
Heparin,9005-49-6,Enoxaparin,DB01225,atrial fibrillation,doid:0060224,original,"Heparin Sodium Injection is indicated for:1. Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension;2.Low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; 3. Prophylaxis and treatment of pulmonary embolism; 4. Atrial fibrillation with embolization; 5. Diagnosis and treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); 6. Prevention of clotting in arterial and cardiac surgery; 7. Prophylaxis and treatment of peripheral arterial embolism. 8. Heparin may also be employed as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes."
Heparin,9005-49-6,Enoxaparin,DB01225,disseminated intravascular coagulation,doid:11247,original,"Heparin Sodium Injection is indicated for:1. Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension;2.Low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; 3. Prophylaxis and treatment of pulmonary embolism; 4. Atrial fibrillation with embolization; 5. Diagnosis and treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); 6. Prevention of clotting in arterial and cardiac surgery; 7. Prophylaxis and treatment of peripheral arterial embolism. 8. Heparin may also be employed as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes."
Heparin,9005-49-6,Enoxaparin,DB01225,cystic fibrosis,doid:1485,repositioned,Treatment of cystic fibrosis
Heparin,9005-49-6,Enoxaparin,DB01225,sickle cell anemia,doid:10923,repositioned,Treatment of sickle cell disease
Histamine,56-92-8,Histamine,DB11320,**adjunct**,,original,"Positive Skin Test Control - Histamine is indicated as an adjunct in allergy skin test for diagnosis, as a positive control to test wheal-flare response of skin for evaluation of skin test response to allergenic extracts."
Histamine,56-92-8,Histamine,DB11320,acute myeloid leukemia,doid:9119,repositioned,Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.
Histamine,56-92-8,Histamine,DB11320,melanoma,doid:1909,repositioned,For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.
Histrelin,76712-82-8,Histrelin,DB06788,central precocious puberty,,original,Treatment of central precocious puberty.
Histrelin,76712-82-8,Histrelin,DB06788,prostate cancer,doid:10283,original,Vantas (Histrelin implant) is indicated in the palliative treatment of advanced prostate cancer.
Histrelin,76712-82-8,Histrelin,DB06788,porphyria,doid:13268,repositioned,"Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria."
Idarubicin,58957-92-9,Idarubicin,DB01177,chronic myeloid leukemia,doid:8552,original,"Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia."
Idarubicin,58957-92-9,Idarubicin,DB01177,lymphoblastic leukemia,doid:1037,repositioned,Treatment of acute lymphoblastic leukemia in pediatric patients.
Idarubicin,58957-92-9,Idarubicin,DB01177,chronic myeloid leukemia,doid:8552,repositioned,Treatment of chronic myelogenous leukemia.
Idarubicin,58957-92-9,Idarubicin,DB01177,myelodysplastic syndrome,doid:0050908,repositioned,Treatment of myelodysplastic syndromes.
Idoxuridine,54-42-2,Idoxuridine,DB00249,keratitis,doid:4677,original,Treatment of keratitis caused by the virus of herpes simplex.
Idoxuridine,54-42-2,Idoxuridine,DB00249,sarcoma,doid:1115,repositioned,Treatment of nonparenchymatous sarcomas.
Ifosfamide,3778-73-2,Ifosfamide,DB01181,testicular germ cell cancer,doid:5557,original,"In combination with certain other approved antineoplastic agents, for third line chemotherapy in the treatment of germ cell testicular cancer."
Ifosfamide,3778-73-2,Ifosfamide,DB01181,bone cancer,doid:184,repositioned,Treatment of bone sarcomas
Ifosfamide,3778-73-2,Ifosfamide,DB01181,sarcoma,doid:1115,repositioned,Treatment of soft tissue sarcomas.
Iloprost solution for infusion,78919-13-8,Iloprost,DB01088,pulmonary hypertension,doid:6432,original,Treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms
Iloprost solution for infusion,78919-13-8,Iloprost,DB01088,Raynaud disease,doid:10300,repositioned,Treatment of Raynaud's phenomenon secondary to systemic sclerosis.
Iloprost solution for infusion,78919-13-8,Iloprost,DB01088,thrombocytopenia,doid:1588,repositioned,Treatment of heparin-associated thrombocytopenia.
Imciromab pentetate,138661-00-4,Indium (111In) imciromab,DB09339,**imaging**,,original,A cardiac imaging agent for detecting the presence and location of myocardial injury in patients with suspected myocardial infarction
Imciromab pentetate,138661-00-4,Indium (111In) imciromab,DB09339,**imaging**,,repositioned,Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.
Immuneglobulin Intravenous (Human),9007-83-4,Immune Globulin Human,DB00028,bacterial infectious disease,doid:104,original,"For prophylaxis of children with clinical or immunologic evidence of human immunodeficiency virus to decrease the frequency of serious and minor bacterial infections and the frequency of hospitalization, and to increase the time free of serious bacterial infection"
Immuneglobulin Intravenous (Human),9007-83-4,Immune Globulin Human,DB00028,common variable immunodeficiency,doid:12177,original,"Replacement therapy in primary (inherited) humoral immunodeficiency disorders, such as common variable immunodeficiency, x-linked agammaglobulinemia, severe combined immunodeficiency, and Wiskott-Aldrich Syndrome."
Immuneglobulin Intravenous (Human),9007-83-4,Immune Globulin Human,DB00028,Bruton-type agammaglobulinemia,doid:14179,original,"Replacement therapy in primary (inherited) humoral immunodeficiency disorders, such as common variable immunodeficiency, x-linked agammaglobulinemia, severe combined immunodeficiency, and Wiskott-Aldrich Syndrome."
Immuneglobulin Intravenous (Human),9007-83-4,Immune Globulin Human,DB00028,severe combined immunodeficiency,doid:627,original,"Replacement therapy in primary (inherited) humoral immunodeficiency disorders, such as common variable immunodeficiency, x-linked agammaglobulinemia, severe combined immunodeficiency, and Wiskott-Aldrich Syndrome."
Immuneglobulin Intravenous (Human),9007-83-4,Immune Globulin Human,DB00028,Wiskott-Aldrich syndrome,doid:9169,original,"Replacement therapy in primary (inherited) humoral immunodeficiency disorders, such as common variable immunodeficiency, x-linked agammaglobulinemia, severe combined immunodeficiency, and Wiskott-Aldrich Syndrome."
Immuneglobulin Intravenous (Human),9007-83-4,Immune Globulin Human,DB00028,Chronic Inflammatory Demyelinating Polyneuropathy,,original,Treatment of Chronic Inflammatory Demyelinating Polyneuropathy.
Immuneglobulin Intravenous (Human),9007-83-4,Immune Globulin Human,DB00028,primary immunodeficiency disease,doid:612,original,Treatment of: 1.Primary Humoral Immunodeficiency. 2. Idiopathic Thrombocytopenic Purpura .
Immuneglobulin Intravenous (Human),9007-83-4,Immune Globulin Human,DB00028,autoimmune thrombocytopenic purpura,doid:8924,repositioned,Treatment for Guillain Barre Syndrome
Immuneglobulin Intravenous (Human),9007-83-4,Immune Globulin Human,DB00028,Guillain-Barre syndrome,doid:12842,repositioned,Treatment of Guillain-Barre syndrome
Immuneglobulin Intravenous (Human),9007-83-4,Immune Globulin Human,DB00028,melanoma,doid:1909,repositioned,Treatment of Stage IIB to IV malignant melanoma
Immuneglobulin Intravenous (Human),9007-83-4,Immune Globulin Human,DB00028,rheumatoid arthritis,doid:7148,repositioned,Treatment of juvenile rheumatoid arthritis.
Immuneglobulin Intravenous (Human),9007-83-4,Immune Globulin Human,DB00028,motor neuron disease,doid:231,repositioned,Treatment of multifocal motor neuropathy 
Immuneglobulin Intravenous (Human),9007-83-4,Immune Globulin Human,DB00028,acute myocarditis,doid:3951,repositioned,Treatment of patients with acute myocarditis.
Immuneglobulin Intravenous (Human),9007-83-4,Immune Globulin Human,DB00028,dermatomyositis,doid:10223,repositioned,Treatment of polymyositis/dermatomyositis.
Immuneglobulin Intravenous (Human),9007-83-4,Immune Globulin Human,DB00028,Stiff-Person syndrome,doid:13366,repositioned,Treatment of stiff-person syndrome
Infliximab,170277-31-3,Infliximab,DB00065,Crohn's disease,doid:8778,original,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy
Infliximab,170277-31-3,Infliximab,DB00065,ulcerative colitis,doid:8577,original,"Remicade is indicated for: 1. Ulcerative Colitis - reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active disease who have had an inadequate response to conventional therapy.  2. Rheumatoid Arthritis in combination with methotrexate - reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. 3. Ankylosing Spondylitis - reducing signs and symptoms in patients with active disease. 4.Psoriatic Arthritis - reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. 5. Plaque Psoriasis - treatment of adult patients with chronic severe (i.e., extensive and /or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. "
Infliximab,170277-31-3,Infliximab,DB00065,rheumatoid arthritis,doid:7148,original,"Remicade is indicated for: 1. Ulcerative Colitis - reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active disease who have had an inadequate response to conventional therapy.  2. Rheumatoid Arthritis in combination with methotrexate - reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. 3. Ankylosing Spondylitis - reducing signs and symptoms in patients with active disease. 4.Psoriatic Arthritis - reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. 5. Plaque Psoriasis - treatment of adult patients with chronic severe (i.e., extensive and /or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. "
Infliximab,170277-31-3,Infliximab,DB00065,ankylosing spondylitis,doid:7147,original,"Remicade is indicated for: 1. Ulcerative Colitis - reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active disease who have had an inadequate response to conventional therapy.  2. Rheumatoid Arthritis in combination with methotrexate - reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. 3. Ankylosing Spondylitis - reducing signs and symptoms in patients with active disease. 4.Psoriatic Arthritis - reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. 5. Plaque Psoriasis - treatment of adult patients with chronic severe (i.e., extensive and /or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. "
Infliximab,170277-31-3,Infliximab,DB00065,psoriatic arthritis,doid:9008,original,"Remicade is indicated for: 1. Ulcerative Colitis - reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active disease who have had an inadequate response to conventional therapy.  2. Rheumatoid Arthritis in combination with methotrexate - reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. 3. Ankylosing Spondylitis - reducing signs and symptoms in patients with active disease. 4.Psoriatic Arthritis - reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. 5. Plaque Psoriasis - treatment of adult patients with chronic severe (i.e., extensive and /or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. "
Infliximab,170277-31-3,Infliximab,DB00065,psoriasis,doid:8893,original,"Remicade is indicated for: 1. Ulcerative Colitis - reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active disease who have had an inadequate response to conventional therapy.  2. Rheumatoid Arthritis in combination with methotrexate - reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. 3. Ankylosing Spondylitis - reducing signs and symptoms in patients with active disease. 4.Psoriatic Arthritis - reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. 5. Plaque Psoriasis - treatment of adult patients with chronic severe (i.e., extensive and /or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. "
Infliximab,170277-31-3,Infliximab,DB00065,sarcoidosis,doid:11335,repositioned,Treatment of chronic sarcoidosis
Infliximab,170277-31-3,Infliximab,DB00065,temporal arteritis,doid:13375,repositioned,Treatment of giant cell arteritis
Infliximab,170277-31-3,Infliximab,DB00065,rheumatoid arthritis,doid:7148,repositioned,Treatment of juvenile rheumatoid arthritis
Infliximab,170277-31-3,Infliximab,DB00065,ulcerative colitis,doid:8577,repositioned,Treatment of pediatric (0 to 16 years of age) ulcerative colitis
Interferon alfa-2a (recombinant),76543-88-9,"Interferon Alfa-2a, Recombinant",DB00034,chronic myeloid leukemia,doid:8552,original,"Roferon-A is indicated for chronic phase, Philadelphia chromosome  positive chronic myelogenous leukemia  patients who are minimally pretreated (within 1 year of diagnosis)."
Interferon alfa-2a (recombinant),76543-88-9,"Interferon Alfa-2a, Recombinant",DB00034,Kaposi's sarcoma,doid:8632,original,Treatment of AIDS related Kaposi's sarcoma.
Interferon alfa-2a (recombinant),76543-88-9,"Interferon Alfa-2a, Recombinant",DB00034,melanoma,doid:1909,repositioned,For the treatment of metastatic malignant melanoma in combination with Teceleukin.
Interferon alfa-2a (recombinant),76543-88-9,"Interferon Alfa-2a, Recombinant",DB00034,esophageal cancer,doid:5041,repositioned,For use in combination with fluorouracil for the treatment of esophageal carcinoma.
Interferon alfa-2b (recombinant),98530-12-2,"Interferon Alfa-2b, Recombinant",DB00105,Kaposi's sarcoma,doid:8632,original,INTRON A is indicated for the treatment of selected patients 18 years of age or older with AIDS-Related Kaposi's Sarcoma.
Interferon alfa-2b (recombinant),98530-12-2,"Interferon Alfa-2b, Recombinant",DB00105,anogenital venereal wart,doid:11168,original,INTRON© A is indicated for:  1. intralesional treatment of selected patients 18 years of age or older with condylomata acuminata involving external surfaces of the genital and perianal areas. 2. the treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease who have a history of blood or blood-product exposure and/or are HCV antibody positive. 3. the treatment of chronic hepatitis B in patients 1 year of age or older with compensated liver disease. Patients who have been serum HBsAg positive for at least 6-months and have evidence of HBV replication (serum HBeAg positive) with elevated serum ALT are candidates for treatment.
Interferon alfa-2b (recombinant),98530-12-2,"Interferon Alfa-2b, Recombinant",DB00105,hepatitis C,doid:1883,original,INTRON© A is indicated for:  1. intralesional treatment of selected patients 18 years of age or older with condylomata acuminata involving external surfaces of the genital and perianal areas. 2. the treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease who have a history of blood or blood-product exposure and/or are HCV antibody positive. 3. the treatment of chronic hepatitis B in patients 1 year of age or older with compensated liver disease. Patients who have been serum HBsAg positive for at least 6-months and have evidence of HBV replication (serum HBeAg positive) with elevated serum ALT are candidates for treatment.
Interferon alfa-2b (recombinant),98530-12-2,"Interferon Alfa-2b, Recombinant",DB00105,hepatitis B,doid:2043,original,INTRON© A is indicated for:  1. intralesional treatment of selected patients 18 years of age or older with condylomata acuminata involving external surfaces of the genital and perianal areas. 2. the treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease who have a history of blood or blood-product exposure and/or are HCV antibody positive. 3. the treatment of chronic hepatitis B in patients 1 year of age or older with compensated liver disease. Patients who have been serum HBsAg positive for at least 6-months and have evidence of HBV replication (serum HBeAg positive) with elevated serum ALT are candidates for treatment.
Interferon alfa-2b (recombinant),98530-12-2,"Interferon Alfa-2b, Recombinant",DB00105,hairy cell leukemia,doid:285,original,"INTRON© A is indicated for: 1. the treatment of patients 18 years of age or older with hairy cell leukemia. 2. as adjuvant to surgical treatment in patients 18 years of age or older with malignant melanoma who are free of disease but at high risk for systemic recurrence, within 56 days of surgery. 3. the initial treatment of clinically aggressive follicular Non-Hodgkin's Lymphoma in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older."
Interferon alfa-2b (recombinant),98530-12-2,"Interferon Alfa-2b, Recombinant",DB00105,non-Hodgkin lymphoma,doid:0060060,original,"INTRON© A is indicated for: 1. the treatment of patients 18 years of age or older with hairy cell leukemia. 2. as adjuvant to surgical treatment in patients 18 years of age or older with malignant melanoma who are free of disease but at high risk for systemic recurrence, within 56 days of surgery. 3. the initial treatment of clinically aggressive follicular Non-Hodgkin's Lymphoma in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older."
Interferon alfa-2b (recombinant),98530-12-2,"Interferon Alfa-2b, Recombinant",DB00105,melanoma,doid:1909,repositioned,Treatment of carcinoma in situ of the urinary bladder.
Interferon alfa-2b (recombinant),98530-12-2,"Interferon Alfa-2b, Recombinant",DB00105,non-Hodgkin lymphoma,doid:0060060,repositioned,Treatment of chronic delta hepatitis.
Interferon alfa-2b (recombinant),98530-12-2,"Interferon Alfa-2b, Recombinant",DB00105,chronic myeloid leukemia,doid:8552,repositioned,Treatment of chronic myelogenous leukemia.
Interferon alfa-2b (recombinant),98530-12-2,"Interferon Alfa-2b, Recombinant",DB00105,cervical cancer,doid:4362,repositioned,Treatment of invasive carcinoma of the cervix.
Interferon alfa-2b (recombinant),98530-12-2,"Interferon Alfa-2b, Recombinant",DB00105,laryngeal benign neoplasm,doid:2598,repositioned,Treatment of laryngeal (respiratory) papillomatosis.
Interferon alfa-2b (recombinant),98530-12-2,"Interferon Alfa-2b, Recombinant",DB00105,ovarian cancer,doid:2394,repositioned,Treatment of ovarian carcinoma.
Interferon alfa-2b (recombinant),98530-12-2,"Interferon Alfa-2b, Recombinant",DB00105,brain cancer,doid:1319,repositioned,Treatment of primary malignant brain tumors.
Interferon beta 1b (recombinant) ,145155-23-3,Interferon beta-1b,DB00068,multiple sclerosis,doid:2377,original,In ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations.
Interferon beta 1b (recombinant) ,145155-23-3,Interferon beta-1b,DB00068,acquired immunodeficiency syndrome,doid:635,repositioned,Treatment of acquired immunodeficiency syndrome.
Interferon beta-1a (recombinant human),145258-61-3,Interferon beta-1a,DB00060,multiple sclerosis,doid:2377,original,Treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations.
Interferon beta-1a (recombinant human),145258-61-3,Interferon beta-1a,DB00060,Kaposi's sarcoma,doid:8632,repositioned,For the intralesional and/or systemic treatment of AIDS-related Kaposi's sarcoma.
Interferon beta-1a (recombinant human),145258-61-3,Interferon beta-1a,DB00060,cutaneous T cell lymphoma,doid:0060061,repositioned,For the systemic treatment of cutaneous T-cell lymphoma.
Interferon beta-1a (recombinant human),145258-61-3,Interferon beta-1a,DB00060,melanoma,doid:1909,repositioned,For the systemic treatment of cutaneous malignant melanoma.
Interferon beta-1a (recombinant human),145258-61-3,Interferon beta-1a,DB00060,rheumatoid arthritis,doid:7148,repositioned,Treatment of juvenile rheumatoid arthritis.
Interferon gamma-1b,82115-62-6,Interferon gamma-1b,DB00033,osteopetrosis,doid:13533,original,"Actimmune is indicated for delaying time to disease progression in patients with severe, malignant osteopetrosis."
Interferon gamma-1b,82115-62-6,Interferon gamma-1b,DB00033,chronic granulomatous disease,doid:3265,original,Actimmune is indicated for reducing the frequency and severity of serious infections associated with chronic granulomatous disease.
Interferon gamma-1b,82115-62-6,Interferon gamma-1b,DB00033,idiopathic pulmonary fibrosis,doid:0050156,repositioned,Treatment of idiopathic pulmonary fibrosis
Itraconazole suspension,84625-61-6,Itraconazole,DB01167,neutropenia,doid:1227,original,Empiric therapy of febrile neutropenic patients with suspected fungal infections.
Itraconazole suspension,84625-61-6,Itraconazole,DB01167,fungal infectious disease,doid:1564,original,"Treatment of the following fungal infections in immunocompromised and non-immunocompromised patients:1. Blastomycosis, pulmonary and extrapulmonary; 2. Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and 3.Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy."
Itraconazole suspension,84625-61-6,Itraconazole,DB01167,otitis externa,doid:9463,repositioned,Topical treatment of fungal otitis externa (otomycosis)
Ketoconazole,65277-42-1,Ketoconazole,DB01026,candidiasis,doid:1508,original,"Treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.Ketoconazole It's also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin."
Ketoconazole,65277-42-1,Ketoconazole,DB01026,nephrotoxicity,,repositioned,For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.
L-cycloserine,68-41-7,Cycloserine,DB00260,tuberculosis,doid:399,original,"Treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate."
L-cycloserine,68-41-7,Cycloserine,DB00260,acute cystitis,doid:13148,original,"Treatment of acute urinary tract infections caused by susceptible strains of gram_positive and gram_negative bacteria, especially Enterobacter spp. and Escherichia coli."
L-cycloserine,68-41-7,Cycloserine,DB00260,Gaucher's disease,doid:1926,repositioned,Treatment of Gaucher's disease.
L-cysteine,52-90-4,L-Cysteine,DB00151,**nutritional addative**,,original,"Cysteine Hydrochloride Injection, USP 0.5 gram is indicated for use only after dilution as an additive to Aminosyn (a crystalline amino acid solution) to meet the intravenous amino acid nutritional requirements of infants receiving total parenteral nutrition."
L-cysteine,52-90-4,L-Cysteine,DB00151,erythropoietic protoporphyria,doid:13270,repositioned,For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.
Lapatinib,388082-78-8,Lapatinib,DB01259,breast cancer,doid:1612,original,"TYKERB, a kinase inhibitor, is indicated in combination with: (1)capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. (2)letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. "
Lapatinib,388082-78-8,Lapatinib,DB01259,esophageal cancer,doid:5041,repositioned,Treatment of ErbB2 positive esophageal cancer
Lapatinib,388082-78-8,Lapatinib,DB01259,stomach cancer,doid:10534,repositioned,Treatment of ErbB2 positive gastric cancer
Leflunomide,75706-12-6,Leflunomide,DB01097,rheumatoid arthritis,doid:7148,original,Indicated in adults for the treatment of active rheumatoid arthritis:1. to reduce signs and symptoms 2. to inhibit structural damage as evidenced by X-ray erosions and joint space narrowing 3. to improve physical function.
Leflunomide,75706-12-6,Leflunomide,DB01097,Transplant Rejection,,repositioned,Prevention of acute and chronic rejection in patients who have received solid organ transplants.
Lenalidomide,191732-72-6,Lenalidomide,DB00480,multiple myeloma,doid:9538,original,For use in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. 
Lenalidomide,191732-72-6,Lenalidomide,DB00480,anemia,doid:2355,original,Treatment of patients with transfusion dependant anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5 q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Lenalidomide,191732-72-6,Lenalidomide,DB00480,chronic lymphocytic leukemia,doid:1040,repositioned,Treatment of chronic lymphocytic leukemia.
Lenalidomide,191732-72-6,Lenalidomide,DB00480,mantle cell lymphoma,doid:0050746,repositioned,Treatment of mantle cell lymphoma
Levocabastine HCl ophthalmic suspension 0.05%,79547-78-7,Levocabastine,DB01106,conjunctivitis,doid:6195,original,Temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
Levocabastine HCl ophthalmic suspension 0.05%,79547-78-7,Levocabastine,DB01106,keratoconjunctivitis,doid:9368,repositioned,Treatment of vernal keratoconjunctivitis.
Levocarnitine,541-15-1,L-Carnitine,DB00583,systemic primary carnitine deficiency disease,doid:14365,original,1. Treatment of primary systemic carnitine deficiency. 2. Acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency.
Levocarnitine,541-15-1,L-Carnitine,DB00583,Secondary carnitine deficiency,,original,Prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.  
Levocarnitine,541-15-1,L-Carnitine,DB00583,Secondary carnitine deficiency,,repositioned,For the prevention of secondary carnitine deficiency in valproic acid toxicity.
Levocarnitine,541-15-1,L-Carnitine,DB00583,cardiomyopathy,doid:0050700,repositioned,Treatment of pediatric cardiomyopathy.
Levocarnitine,541-15-1,L-Carnitine,DB00583,mitochondrial myopathy,doid:699,repositioned,Treatment of zidovudine-induced mitochondrial myopathy.
Levofloxacin,100986-85-4,Levofloxacin,DB01137,bacterial infectious disease,doid:104,original,"Treatment of adults (_18 years of age) with mild, moderate, and severe infections caused by susceptible strains of the designated microorganisms in the conditions listed in the label.  For details see: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17731#nlm34067-9"
Levofloxacin,100986-85-4,Levofloxacin,DB01137,corneal ulcer,doid:8463,original,"Treatment of corneal ulcer caused by susceptible strains of the following bacteria: GRAM-POSITIVE BACTERIA: Corynebacterium species,  Staphylococcus aureus, Staphylococcus epidermidis,  Streptococcus pneumoniae, Viridans group streptococci. GRAM-NEGATIVE BACTERIA: Pseudomonas aeruginosa Serratia marcescens."
Levofloxacin,100986-85-4,Levofloxacin,DB01137,primary bacterial infectious disease,doid:0050338,repositioned,Treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients.
Lidocaine,137-58-6,Lidocaine,DB00281,**anesthetic**,,original,Local anaesthesia
Lidocaine,137-58-6,Lidocaine,DB00281,asthma,doid:2841,repositioned,Oral corticosteroid-dependent asthma
Liposomal ciprofloxacin for inhalation,85721-33-1,Ciprofloxacin,DB00537,bacterial infectious disease,doid:104,original,Treatment of infections caused by susceptible strains of the designated microorganisms. See detailed list at: http://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=ciprofloxacin
Liposomal ciprofloxacin for inhalation,85721-33-1,Ciprofloxacin,DB00537,cystic fibrosis,doid:1485,repositioned,Management of cystic fibrosis
Liposomal cyclosporine,59865-13-3,Cyclosporine,DB00091,bronchiolitis obliterans,doid:2799,repositioned,Treatment of bronchiolitis obliterans 
Liposomal doxorubicin hydrochloride,23214-92-8,Doxorubicin,DB00997,Kaposi's sarcoma,doid:8632,original,DOXIL (doxorubicin HCl liposome injection) is an anthracycline topoisomerase inhibitor indicated for: 1. Ovarian cancer - After failure of platinum-based chemotherapy. 2. AIDS-related Kaposi's Sarcoma -after failure of prior combination chemotherapy or intolerance to such therapy. 3. Multiple Myeloma - In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy.
Liposomal doxorubicin hydrochloride,23214-92-8,Doxorubicin,DB00997,multiple myeloma,doid:9538,original,DOXIL (doxorubicin HCl liposome injection) is an anthracycline topoisomerase inhibitor indicated for: 1. Ovarian cancer - After failure of platinum-based chemotherapy. 2. AIDS-related Kaposi's Sarcoma -after failure of prior combination chemotherapy or intolerance to such therapy. 3. Multiple Myeloma - In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy.
Liposomal doxorubicin hydrochloride,23214-92-8,Doxorubicin,DB00997,sarcoma,doid:1115,repositioned,Treatment of soft tissue sarcomas.
Liposomal topotecan hydrochloride,119413-54-6,Topotecan,DB01030,ovarian cancer,doid:2394,original,"HYCAMTIN for Injection is a topoisomerase inhibitor indicated for:1. metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy. 2. small cell lung cancer sensitive disease after failure of first-line chemotherapy. 3. combination therapy with cisplatin for stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy."
Liposomal topotecan hydrochloride,119413-54-6,Topotecan,DB01030,lung small cell carcinoma,doid:5409,original,"HYCAMTIN for Injection is a topoisomerase inhibitor indicated for:1. metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy. 2. small cell lung cancer sensitive disease after failure of first-line chemotherapy. 3. combination therapy with cisplatin for stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy."
Liposomal topotecan hydrochloride,119413-54-6,Topotecan,DB01030,cervical cancer,doid:4362,original,"HYCAMTIN for Injection is a topoisomerase inhibitor indicated for:1. metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy. 2. small cell lung cancer sensitive disease after failure of first-line chemotherapy. 3. combination therapy with cisplatin for stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy."
Liposomal topotecan hydrochloride,119413-54-6,Topotecan,DB01030,malignant glioma,doid:3070,repositioned,Treatment of gliomas
Lyposomal cisplatin,15663-27-1,Cisplatin,DB00515,testicular cancer,doid:2998,original,"1. Metastatic Testicular Tumors. In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. 2. Advanced Bladder Cancer. It is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy."
Lyposomal cisplatin,15663-27-1,Cisplatin,DB00515,bladder urothelial carcinoma,doid:4006,original,"1. Metastatic Testicular Tumors. In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. 2. Advanced Bladder Cancer. It is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy."
Lyposomal cisplatin,15663-27-1,Cisplatin,DB00515,ovarian cancer,doid:2394,original,"As therapy for Metastatic Ovarian Tumors. In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. As a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received PLATINOL therapy."
Lyposomal cisplatin,15663-27-1,Cisplatin,DB00515,osteosarcoma,doid:3347,repositioned,Treatment of osteogenic sarcoma metastatic to the lung
Mannitol ,69-65-8,Mannitol,DB00742,kidney failure,doid:1074,original,"Mannitol Injection is indicated for: Promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established. Reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass. Reduction of elevated intraocular pressure when the pressure cannot be lowered by other means. Promotion of urinary excretion of toxins."
Mannitol ,69-65-8,Mannitol,DB00742,intracranial hypertension,doid:9428,original,"Mannitol Injection is indicated for: Promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established. Reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass. Reduction of elevated intraocular pressure when the pressure cannot be lowered by other means. Promotion of urinary excretion of toxins."
Mannitol ,69-65-8,Mannitol,DB00742,intraocular pressure,,original,"Mannitol Injection is indicated for: Promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established. Reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass. Reduction of elevated intraocular pressure when the pressure cannot be lowered by other means. Promotion of urinary excretion of toxins."
Mannitol ,69-65-8,Mannitol,DB00742,bronchiectasis,doid:9563,repositioned,For use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis
Mazindol,22232-71-9,Mazindol,DB00579,obesity,doid:9970,original,Used as a short-term supplement to diet and exercise in the treatment of obesity. 
Mazindol,22232-71-9,Mazindol,DB00579,Duchenne muscular dystrophy,doid:11723,repositioned,Treatment of Duchenne muscular dystrophy.
Mecamylamine,60-40-2,Mecamylamine,DB00657,hypertension,doid:10763,original,Moderately severe to severe essential hypertension and uncomplicated cases of malignant hypertension
Mecamylamine,60-40-2,Mecamylamine,DB00657,attention deficit hyperactivity disorder,doid:1094,repositioned,ADHD
Mecasermin,68562-41-4,Mecasermin,DB01277,growth failure,,original,Long-term treatment of growth failure in children with severe primary insulin growth factor-1 deficiency or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone.  
Mecasermin,68562-41-4,Mecasermin,DB01277,amyotrophic lateral sclerosis,doid:332,repositioned,Treatment of amyotrophic lateral sclerosis.
Mecasermin,68562-41-4,Mecasermin,DB01277,growth hormone deficiency,,repositioned,Treatment of antibody-mediated growth hormone resistance in patients with isolated growth hormone deficiency Ia.
Mecasermin,68562-41-4,Mecasermin,DB01277,dermatomyositis,doid:10223,repositioned,Treatment of post-poliomyelitis syndrome.
Mecasermin,68562-41-4,Mecasermin,DB01277,short bowel syndrome,doid:10605,repositioned,Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.
Mecasermin rinfabate,68562-41-4,Mecasermin,DB01277,myotonic disease,doid:450,repositioned,Treatment of myotonic dystrophy.
Medroxyprogesterone acetate,520-85-4,Medroxyprogesterone acetate,DB00603,pregnancy,,original,Medroxyprogesterone acetate injectable suspension is indicated only for the prevention of pregnancy.
Medroxyprogesterone acetate,520-85-4,Medroxyprogesterone acetate,DB00603,endometrial carcinoma,doid:2871,original,"Medroxyprogesterone acetate injection (suspension) is indicated as adjunctive therapy and palliative treatment of inoperable, recurrent, and metastatic endometrial or renal carcinoma."
Medroxyprogesterone acetate,520-85-4,Medroxyprogesterone acetate,DB00603,renal cell carcinoma,doid:4450,original,"Medroxyprogesterone acetate injection (suspension) is indicated as adjunctive therapy and palliative treatment of inoperable, recurrent, and metastatic endometrial or renal carcinoma."
Medroxyprogesterone acetate,520-85-4,Medroxyprogesterone acetate,DB00603,amenorrhea,doid:13938,original,"Treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer.It is also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets."
Medroxyprogesterone acetate,520-85-4,Medroxyprogesterone acetate,DB00603,autoimmune thrombocytopenic purpura,doid:8924,repositioned,Treatment of immune thrombocytopenic purpura.
Melphalan,148-82-3,Melphalan,DB01042,multiple myeloma,doid:9538,original,ALKERAN Tablets are indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary
Melphalan,148-82-3,Melphalan,DB01042,ovary epithelial cancer,doid:2152,original,ALKERAN Tablets are indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary
Melphalan,148-82-3,Melphalan,DB01042,melanoma,doid:1909,repositioned,For use in hyperthermic regional limb perfusion to treat metastatic melanoma of the extremity.
Melphalan,148-82-3,Melphalan,DB01042,**stem cell transplant**,,repositioned,High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation.
Melphalan,148-82-3,Melphalan,DB01042,neuroendocrine tumor,doid:169,repositioned,Treatment of neuroendocrine tumors 
Mepivacaine,96-88-8,Mepivacaine,DB00961,**anesthestic**,,original,Indicated for production of local anesthesia for dental procedures by infiltration or nerve block in adults and pediatric patients.
Mepivacaine,96-88-8,Mepivacaine,DB00961,neuropathy,doid:870,repositioned,Treatment of painful HIV-associated neuropathy
Mepivacaine,96-88-8,Mepivacaine,DB00961,postherpetic neuralgia,,repositioned,Treatment of postherpetic neuralgia
Mesalamine,89-57-6,Mesalazine,DB00244,ulcerative colitis,doid:8577,original,Maintenance of remission of ulcerative colitis in patients 18 years of age and older.
Mesalamine,89-57-6,Mesalazine,DB00244,ulcerative colitis,doid:8577,repositioned,"Treatment of active, mild to moderate ulcerative colitis in children 5 to 17 years."
Mesna,19767-45-4,Mesna,DB09110,hemorrhagic cystitis,doid:0050859,original,For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. 
Mesna,19767-45-4,Mesna,DB09110,urotoxicity,,repositioned,Inhibition of the urotoxic effects induced by oxazaphosphorine compounds such as cyclophosphamide.
Methoxsalen,298-81-7,Methoxsalen,DB00553,psoriasis,doid:8893,original,"A. Photochemotherapy (methoxsalen with long wave UVA radiation) is indicated for the symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy.  B. Photochemotherapy (methoxsalen with long wave ultraviolet radiation) is indicated for the repigmentation of idiopathic vitiligo.C. Photopheresis (methoxsalen with long wave ultraviolet radiation of white blood cells) is indicated for use with the UVAR* System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma in persons who have not been responsive to other forms of treatment."
Methoxsalen,298-81-7,Methoxsalen,DB00553,vitiligo,doid:12306,original,"A. Photochemotherapy (methoxsalen with long wave UVA radiation) is indicated for the symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy.  B. Photochemotherapy (methoxsalen with long wave ultraviolet radiation) is indicated for the repigmentation of idiopathic vitiligo.C. Photopheresis (methoxsalen with long wave ultraviolet radiation of white blood cells) is indicated for use with the UVAR* System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma in persons who have not been responsive to other forms of treatment."
Methoxsalen,298-81-7,Methoxsalen,DB00553,cutaneous T cell lymphoma,doid:0060061,original,"A. Photochemotherapy (methoxsalen with long wave UVA radiation) is indicated for the symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy.  B. Photochemotherapy (methoxsalen with long wave ultraviolet radiation) is indicated for the repigmentation of idiopathic vitiligo.C. Photopheresis (methoxsalen with long wave ultraviolet radiation of white blood cells) is indicated for use with the UVAR* System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma in persons who have not been responsive to other forms of treatment."
Methoxsalen,298-81-7,Methoxsalen,DB00553,Transplant Rejection,,repositioned,For the prevention of acute rejection of cardiac allografts.
Methoxsalen,298-81-7,Methoxsalen,DB00553,systemic scleroderma,doid:418,repositioned,For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.
Metronidazole,443-48-1,Metronidazole,DB00916,trichomoniasis,doid:1947,original,"Metronidazole is indicated for treatment of Trichomoniasis (both symptomatic and asymptomatic), Asymptomatic consorts and anaerobi bacteria infections (see details at:http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=4767#nlm34067-9)"
Metronidazole,443-48-1,Metronidazole,DB00916,protozoal dysentery,doid:14397,original,Treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess.
Metronidazole,443-48-1,Metronidazole,DB00916,pouchitis,,repositioned,Treatment of pouchitis
Metronidazole (topical),443-48-1,Metronidazole,DB00916,rosacea,doid:8881,original,Metronidazole tropical treatment is indicated for inflammtory papules and pustules or rosacea.
Metronidazole (topical),443-48-1,Metronidazole,DB00916,Crohn's disease,doid:8778,repositioned,Topical treatment of active perianal Crohn's disease
Metronidazole (topical),443-48-1,Metronidazole,DB00916,decubitus ulcer,doid:8717,repositioned,"Treatment of grade III and IV, anaerobically infected, decubitus ulcers."
Metronidazole (topical),443-48-1,Metronidazole,DB00916,dermatitis,doid:2723,repositioned,Treatment of perioral dermatitis.
Metyrosine ,672-87-7,Metyrosine,DB00765,adrenal medulla cancer,doid:5719,original,Treatment of patients with pheochromocytoma for:1. Preoperative preparation of patients for surgery; 2. Management of patients when surgery is contraindicated; 3. Chronic treatment of patients with malignant pheochromocytoma.
Metyrosine ,672-87-7,Metyrosine,DB00765,velocardiofacial syndrome,doid:12583,repositioned,Treatment of velocardiofacial syndrome associated psychosis. 
Microbubble contrast agent,,Perflutren,DB00556,**imaging**,,original,Activated DEFINITY© (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
Microbubble contrast agent,,Perflutren,DB00556,**imaging**,,repositioned,Intraoperative aid in the identification and localization of intracranial tumors.
Midazolam HCl,59467-96-8,Midazolam,DB00683,**anesthestic**,,original,"1. Intramuscularly or intravenously for preoperative sedation/anxiolysis/amnesia; 2. Intravenously as an agent for sedation/anxiolysis/amnesia prior to or during diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, oncology procedures, radiologic procedures, suture of lacerations and other procedures either alone or in combination with other CNS depressants; 3. Intravenously for induction of general anesthesia, before administration of other anesthetic agents. 4. Continuous intravenous infusion for sedation of intubated and mechanically ventilated patients as a component of anesthesia or during treatment in a critical care setting."
Midazolam HCl,59467-96-8,Midazolam,DB00683,epilepsy,doid:1826,repositioned,Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam
Midazolam nasal spray,59467-70-8,Midazolam,DB00683,epilepsy,doid:1826,repositioned,"Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)."
Mifepristone,84371-65-3,Mifepristone,DB00834,intrauterine pregnancy,,original,Medical termination of intrauterine pregnancy through 49 days_pregnancy.
Mifepristone,84371-65-3,Mifepristone,DB00834,Cushing's syndrome,doid:12252,repositioned,Treatment of Cushing's syndrome secondary to ectopic ACTH secretion
Miglustat,72599-27-0,Miglustat,DB00419,Gaucher's disease,doid:1926,original,"Treatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due to constraints such as allergy, hypersensitivity, or poor venous access). "
Miglustat,72599-27-0,Miglustat,DB00419,Niemann-Pick disease,doid:14504,repositioned,"Treatment of the neurological manifestations of Niemann-Pick disease,type C."
Milnacipran,92623-85-3,Milnacipran,DB04896,mental depression,doid:1596,original,Depression
Milnacipran,92623-85-3,Milnacipran,DB04896,fibromyalgia,doid:631,repositioned,Fibromyalgia syndrome
Minocycline HCL,13614-97-8,Minocycline,DB01017,bacterial infectious disease,doid:104,original,Treatment of the infections due to susceptible strains of the designated microorganisms: see detailed list in http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=4676#nlm34067-9
Minocycline HCL,13614-97-8,Minocycline,DB01017,malignant pleural effusion,,repositioned,Treatment of chronic malignant pleural effusion.
Minocycline HCL,13614-97-8,Minocycline,DB01017,sarcoidosis,doid:11335,repositioned,Treatment of sarcoidosis
Minoxidil,38304-91-5,Minoxidil,DB00350,hypertension,doid:10763,original,Hypertension
Minoxidil,38304-91-5,Minoxidil,DB00350,hair loss,,repositioned,Hair loss
Misoprostol,59122-46-2,Misoprostol,DB00929,gastric ulcer,doid:10808,original,"Reducing the risk of NSAID_induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer."
Misoprostol,59122-46-2,Misoprostol,DB00929,Intrauterine fetal death,,repositioned,Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.
Mitomycin-C,50-07-7,Mitomycin,DB00305,gastric adenocarcinoma,doid:3717,original,Mitomycin has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. 
Mitomycin-C,50-07-7,Mitomycin,DB00305,pancreatic adenocarcinoma,doid:4074,original,Mitomycin has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. 
Mitomycin-C,50-07-7,Mitomycin,DB00305,glaucoma,doid:1686,repositioned,Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.
Mycophenolate mofetil,128794-94-5,Mycophenolate mofetil,DB00688,Transplant Rejection,,original,"Mycophenolate mofetil is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids."
Mycophenolate mofetil,128794-94-5,Mycophenolate mofetil,DB00688,pemphigus vulgaris,,repositioned,Treatment of pemphigus vulgaris 
N-acetylcysteine,616-91-1,Acetylcysteine,DB06151,chronic obstructive pulmonary disease,doid:3083,original,"Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as:Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis); Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); Pulmonary complications associated with surgery; Use during anesthesia; Post-traumatic chest conditions; Atelectasis due to mucous obstruction; Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) ."
N-acetylcysteine,616-91-1,Acetylcysteine,DB06151,pneumonia,doid:552,,"Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as:Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis); Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); Pulmonary complications associated with surgery; Use during anesthesia; Post-traumatic chest conditions; Atelectasis due to mucous obstruction; Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) ."
N-acetylcysteine,616-91-1,Acetylcysteine,DB06151,bronchitis,doid:6132,,"Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as:Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis); Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); Pulmonary complications associated with surgery; Use during anesthesia; Post-traumatic chest conditions; Atelectasis due to mucous obstruction; Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) ."
N-acetylcysteine,616-91-1,Acetylcysteine,DB06151,croup,doid:9395,,"Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as:Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis); Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); Pulmonary complications associated with surgery; Use during anesthesia; Post-traumatic chest conditions; Atelectasis due to mucous obstruction; Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) ."
N-acetylcysteine,616-91-1,Acetylcysteine,DB06151,Atelectasis,,,"Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as:Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis); Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); Pulmonary complications associated with surgery; Use during anesthesia; Post-traumatic chest conditions; Atelectasis due to mucous obstruction; Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) ."
N-acetylcysteine,616-91-1,Acetylcysteine,DB06151,cystic fibrosis,doid:1485,,"Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as:Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis); Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); Pulmonary complications associated with surgery; Use during anesthesia; Post-traumatic chest conditions; Atelectasis due to mucous obstruction; Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) ."
N-acetylcysteine,616-91-1,Acetylcysteine,DB06151,hepatotoxicity,,original,"Administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, it is indicated to prevent or lessen hepatic injury "
N-acetylcysteine,616-91-1,Acetylcysteine,DB06151,acute liver failure,,repositioned,Treatment of acute liver failure 
Nabumetone,42924-53-8,Nabumetone,DB00461,osteoarthritis,doid:8398,original,It is indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.
Nabumetone,42924-53-8,Nabumetone,DB00461,rheumatoid arthritis,doid:7148,original,It is indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.
Nabumetone,42924-53-8,Nabumetone,DB00461,rheumatoid arthritis,doid:7148,repositioned,Treatment of pediatric juvenile rheumatoid arthritis.
Nevirapine,129618-40-2,Nevirapine,DB00238,human immunodeficiency virus infectious disease,doid:526,original,Use in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Nevirapine,129618-40-2,Nevirapine,DB00238,human immunodeficiency virus infectious disease,doid:526,repositioned,Prevention of HIV infection in pediatric patients under the age of 16 years.
Nilotinib,641571-10-0,Nilotinib,DB04868,chronic myeloid leukemia,doid:8552,original,For the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia in adult patients resistant to or intolerant to prior therapy that included imatinib.
Nilotinib,641571-10-0,Nilotinib,DB04868,gastrointestinal stromal tumor,doid:9253,repositioned,Treatment of gastrointestinal stromal tumors.
Nitazoxanide,55981-09-4,Nitazoxanide,DB00507,diarrhea,doid:13250,original,Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia
Nitazoxanide,55981-09-4,Nitazoxanide,DB00507,amebiasis,doid:9181,repositioned,Treatment for intestinal amebiasis
Nitisinone,104206-65-7,Nitisinone,DB00348,tyrosinemia,doid:9275,original,Adjunctive therapy to dietary  restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1.
Nitisinone,104206-65-7,Nitisinone,DB00348,alkaptonuria,doid:9270,repositioned,Treatment of alkaptonuria
Nitric oxide,10102-43-9,Nitric Oxide,DB00435,pulmonary hypertension,doid:6432,original,"In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation."
Nitric oxide,10102-43-9,Nitric Oxide,DB00435,sarcoidosis,doid:11335,repositioned,Diagnosis of sarcoidosis
Nitric oxide,10102-43-9,Nitric Oxide,DB00435,chronic obstructive pulmonary disease,doid:3083,repositioned,To reduce the risk of chronic lung disease in premature neonates
Nitric oxide,10102-43-9,Nitric Oxide,DB00435,adult respiratory distress syndrome,doid:11394,repositioned,Treatment of acute respiratory distress syndrome in adults.
Nitric oxide,10102-43-9,Nitric Oxide,DB00435,acute chest syndrome,doid:1584,repositioned,Use in combination with a drug delivery device for acute treatment of sickle cell vaso-occlusive crisis (pain crises).
Nitroprusside,15078-28-1,Nitroprusside,DB00325,hypertension,doid:10763,original,1. The immediate reduction of blood pressure of patients in hypertensive crises. 2. Producing controlled hypotension in order to reduce bleeding during surgery. 3. The treatment of acute congestive heart failure.
Nitroprusside,15078-28-1,Nitroprusside,DB00325,congestive heart failure,doid:6000,original,1. The immediate reduction of blood pressure of patients in hypertensive crises. 2. Producing controlled hypotension in order to reduce bleeding during surgery. 3. The treatment of acute congestive heart failure.
Nitroprusside,15078-28-1,Nitroprusside,DB00325,intracranial berry aneurysm,doid:0060228,repositioned,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.
Omega-3 (n-3) polyunsaturated fatty acids,,,,IgA glomerulonephritis,doid:2986,repositioned,Treatment of IgA nephropathy.
Omegaven emulsion,,,,liver disease,doid:409,repositioned,Treatment of parenteral nutrition-associated liver disease
Oxaliplatin,61825-94-3,Oxaliplatin,DB00526,colon cancer,doid:219,original,"Used in combination with infusional 5-FU/LV, it is indicated for: 1. adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.  2. treatment of advanced colorectal cancer. "
Oxaliplatin,61825-94-3,Oxaliplatin,DB00526,colorectal cancer,doid:9256,original,"Used in combination with infusional 5-FU/LV, it is indicated for: 1. adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.  2. treatment of advanced colorectal cancer. "
Oxaliplatin,61825-94-3,Oxaliplatin,DB00526,ovarian cancer,doid:2394,repositioned,Treatment of ovarian cancer.
Oxandrolone,53-39-4,Oxandrolone,DB00621,**weight-gain**,,original,"As adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis."
Oxandrolone,53-39-4,Oxandrolone,DB00621,acquired immunodeficiency syndrome,doid:635,repositioned,Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.
Oxandrolone,53-39-4,Oxandrolone,DB00621,constitutional delay of growth and puberty,,repositioned,Treatment of constitutional delay of growth and puberty.
Oxandrolone,53-39-4,Oxandrolone,DB00621,alcoholic hepatitis,doid:12351,repositioned,Treatment of moderate/severe acute alcoholic hepatitis in the presence of moderate protein calorie malnutrition.
Oxandrolone,53-39-4,Oxandrolone,DB00621,Duchenne muscular dystrophy,doid:11723,repositioned,Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.
Oxandrolone,53-39-4,Oxandrolone,DB00621,Turner syndrome,doid:3491,repositioned,Treatment of short stature associated with Turner's syndrome.
Paclitaxel,33069-62-4,Paclitaxel,DB01229,cancer,doid:162,original,Cancer
Paclitaxel,33069-62-4,Paclitaxel,DB01229,Kaposi's sarcoma,doid:8632,original,For the second-line treatment of AIDS-related Kaposi_s sarcoma.
Paclitaxel,33069-62-4,Paclitaxel,DB01229,breast cancer,doid:1612,original,Paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.
Paclitaxel,33069-62-4,Paclitaxel,DB01229,coronary restenosis,doid:4247,repositioned,Restenosis
Paclitaxel,33069-62-4,Paclitaxel,DB01229,pancreatic cancer,doid:1793,repositioned,Treatment of pancreatic cancer
Paclitaxel aqueous gel,33069-62-4,Paclitaxel,DB01229,non-small cell lung carcinoma,doid:3908,original,"Paclitaxel in combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy."
Paclitaxel aqueous gel,33069-62-4,Paclitaxel,DB01229,ovarian cancer,doid:2394,original,"Paclitaxel is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, Paclitaxel is indicated in combination with cisplatin"
Paclitaxel aqueous gel,33069-62-4,Paclitaxel,DB01229,brain cancer,doid:1319,repositioned,Treatment of brain cancer.
Paclitaxel aqueous gel,33069-62-4,Paclitaxel,DB01229,esophageal cancer,doid:5041,repositioned,Treatment of esophageal cancer
Paclitaxel protein-bound particles for injection suspension,33069-62-4,Paclitaxel,DB01229,melanoma,doid:1909,repositioned,Treatment of stage IIb to IV melanoma.
"Paclitaxel, micellar",33069-62-4,Paclitaxel,DB01229,ovarian cancer,doid:2394,repositioned,Treatment of ovarian cancer
Pazopanib,444731-52-6,Pazopanib,DB06589,renal cell carcinoma,doid:4450,original,Treatment of patients with advanced renal cell carcinoma.
Pazopanib,444731-52-6,Pazopanib,DB06589,sarcoma,doid:1115,repositioned,Treatment of soft tissue sarcomas
Peginterferon alfa-2a,198153-51-4,Peginterferon alfa-2a,DB00008,hepatitis C,doid:1883,original,"1. PEGASYS, peginterferon alfa-2a, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that is clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy).2.PEGASYS is indicated for the treatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation."
Peginterferon alfa-2a,198153-51-4,Peginterferon alfa-2a,DB00008,hepatitis B,doid:2043,original,"1. PEGASYS, peginterferon alfa-2a, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that is clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy).2.PEGASYS is indicated for the treatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation."
Peginterferon alfa-2a,198153-51-4,Peginterferon alfa-2a,DB00008,hairy cell leukemia,doid:285,original,Treatment of hairy cell leukemia in patients 18 years of age or older.
Peginterferon alfa-2a,198153-51-4,Peginterferon alfa-2a,DB00008,chronic myeloid leukemia,doid:8552,repositioned,Treatment of chronic myelogenous leukemia.
Peginterferon alfa-2b,99210-65-8,Peginterferon alfa-2b,DB00022,hepatitis C,doid:1883,original,1. Combination therapy with REBETOL (ribavirin): Chronic Hepatitis C (CHC) in patients _3 years with compensated liver disease. 2. Monotherapy: CHC in patients (_18 years) with compensated liver disease previously untreated with interferon alpha. 
Peginterferon alfa-2b,99210-65-8,Peginterferon alfa-2b,DB00022,hepatitis D,doid:2047,repositioned,Treatment of chronic delta hepatitis.
Peginterferon alfa-2b,99210-65-8,Peginterferon alfa-2b,DB00022,melanoma,doid:1909,repositioned,Treatment of malignant melanoma stages IIb through IV. 
Pentagastrin,5534-95-2,Pentagastrin,DB00183,**diagnostic agent**,,original,Testing agent to help diagnose problems or diseases of the stomach
Pentagastrin,5534-95-2,Pentagastrin,DB00183,**diagnostic agent**,,repositioned,To aid in the diagnosis of medullary thyroid carcinoma
Pentosan polysulfate sodium,37300-21-3,Pentosan Polysulfate,DB00686,interstitial cystitis,doid:13949,original,Relief of bladder pain or discomfort associated with interstitial cystitis.
Pentosan polysulfate sodium,37300-21-3,Pentosan Polysulfate,DB00686,sickle cell anemia,doid:10923,repositioned,Treatment of sickle cell disease. 
Pentostatin,53910-25-1,Pentostatin,DB00552,hairy cell leukemia,doid:285,original,"Single agent treatment for adult patients with alpha-interferon-refractory hairy cell leukemia with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms."
Pentostatin,53910-25-1,Pentostatin,DB00552,cutaneous T cell lymphoma,doid:0060061,repositioned,Treatment of cutaneous T-cell lymphoma.
Pentostatin,53910-25-1,Pentostatin,DB00552,chronic lymphocytic leukemia,doid:1040,repositioned,Treatment of patients with chronic lymphocytic leukemia.
Phentolamine,50-60-2,Phentolamine,DB00692,hypertension,doid:10763,original,Hypertension
Phentolamine,50-60-2,Phentolamine,DB00692,night blindness,doid:8499,repositioned,Impaired night vision
Polyphenon E,,,,anogenital venereal wart,doid:11168,original,Veregen© is a topical ointment indicated for the treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.
Polyphenon E,,,,chronic lymphocytic leukemia,doid:1040,repositioned,Treatment of chronic lymphocytic leukemia
Porfimer sodium,87806-31-3,Porfimer,DB00707,esophageal cancer,doid:5041,original,"1. Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy.  2. Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial non-small-cell lung cancer (NSCLC). 3. Treatment of microinvasive endobronchial NSCLC in patients for whom surgery and radiotherapy are not indicated.  4. Ablation of high-grade dysplasia in Barrett_s esophagus patients who do not undergo esophagectomy."
Porfimer sodium,87806-31-3,Porfimer,DB00707,non-small cell lung carcinoma,doid:3908,original,"1. Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy.  2. Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial non-small-cell lung cancer (NSCLC). 3. Treatment of microinvasive endobronchial NSCLC in patients for whom surgery and radiotherapy are not indicated.  4. Ablation of high-grade dysplasia in Barrett_s esophagus patients who do not undergo esophagectomy."
Porfimer sodium,87806-31-3,Porfimer,DB00707,Barrett's esophagus,doid:9206,original,"1. Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy.  2. Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial non-small-cell lung cancer (NSCLC). 3. Treatment of microinvasive endobronchial NSCLC in patients for whom surgery and radiotherapy are not indicated.  4. Ablation of high-grade dysplasia in Barrett_s esophagus patients who do not undergo esophagectomy."
Porfimer sodium,87806-31-3,Porfimer,DB00707,bladder urothelial carcinoma,doid:4006,repositioned,For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.
Porfimer sodium,87806-31-3,Porfimer,DB00707,bile duct cancer,doid:4606,repositioned,Treatment of cholangiocarcinoma
Pralatrexate,146464-95-1,Pralatrexate,DB06813,cutaneous T cell lymphoma,doid:0060061,original,Treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Pralatrexate,146464-95-1,Pralatrexate,DB06813,bladder urothelial carcinoma,doid:4006,repositioned,Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder
Pralatrexate,146464-95-1,Pralatrexate,DB06813,diffuse large B-cell lymphoma,doid:0050745,repositioned,Treatment of diffuse large B-cell lymphoma
Pralatrexate,146464-95-1,Pralatrexate,DB06813,follicular lymphoma,doid:0050873,repositioned,Treatment of follicular lymphoma
Pramipexole ,104632-26-0,Pramipexole,DB00413,Parkinson's disease,doid:14330,original,1. the treatment of the signs and symptoms of idiopathic Parkinson's disease. 2. the treatment of moderate-to-severe primary Restless Legs Syndrome.
Pramipexole ,104632-26-0,Pramipexole,DB00413,restless legs syndrome,doid:0050425,original,1. the treatment of the signs and symptoms of idiopathic Parkinson's disease. 2. the treatment of moderate-to-severe primary Restless Legs Syndrome.
Pramipexole ,104632-26-0,Pramipexole,DB00413,Gilles de la Tourette syndrome,doid:11119,repositioned,Treatment of Tourette's syndrome in pediatric patients
Praziquantel,55268-74-1,Praziquantel,DB01058,schistosomiasis,doid:1395,original,"Treatment of infections due to: all species of schistosoma (e.g. Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium), and infections due to the liver flukes, Clonorchis sinensis/ Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated)."
Praziquantel,55268-74-1,Praziquantel,DB01058,clonorchiasis,doid:13767,original,"Treatment of infections due to: all species of schistosoma (e.g. Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium), and infections due to the liver flukes, Clonorchis sinensis/ Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated)."
Praziquantel,55268-74-1,Praziquantel,DB01058,opisthorchiasis,doid:13768,original,"Treatment of infections due to: all species of schistosoma (e.g. Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium), and infections due to the liver flukes, Clonorchis sinensis/ Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated)."
Praziquantel,55268-74-1,Praziquantel,DB01058,cysticercosis,doid:10079,repositioned,Treatment of neurocysticercosis.
Primaquine phosphate,90-34-6,Primaquine,DB01087,Plasmodium vivax malaria,doid:12978,original,For the radical cure (prevention of relapse) of vivax malaria.
Primaquine phosphate,90-34-6,Primaquine,DB01087,pneumocystosis,doid:11339,repositioned,For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.
Procarbazine hydrochloride,671-16-9,Procarbazine,DB01168,Hodgkin's lymphoma,doid:8567,original,"Matulane is indicated for use in combination with other anticancer drugs for the treatment of Stage III and IV Hodgkin's disease. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen."
Procarbazine hydrochloride,671-16-9,Procarbazine,DB01168,malignant glioma,doid:3070,repositioned,Treatment of malignant glioma 
Progesterone,57-83-0,Progesterone,DB00396,amenorrhea,doid:13938,original,"Progesterone injection solution is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer."
Progesterone,57-83-0,Progesterone,DB00396,infertility,doid:5223,original,Progesterone tablet is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology treatment program for infertile women.
Progesterone,57-83-0,Progesterone,DB00396,endometrial hyperplasia,,original,Prometrium (progesterone)  capsule is indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea.
Progesterone,57-83-0,Progesterone,DB00396,infertility,doid:5223,repositioned,Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.
Progesterone,57-83-0,Progesterone,DB00396,traumatic brain injury,,repositioned,For early intervention in the treatment of moderate to severe closed-head traumatic brain injury
Propranolol,525-66-6,Propranolol,DB00571,hypertension,doid:10763,original,1. Management of hypertension.  2. Decrease angina frequency and increase exercise tolerance in patients with angina pectoris.  3. Control ventricular rate in patients with atrial fibrillation and a rapid ventricular response.  4. Reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable.  5. Prophylaxis of common migraine headache.   6. Management of familial or hereditary essential tremor.  7. Improves NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.  8. As an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors
Propranolol,525-66-6,Propranolol,DB00571,intermediate coronary syndrome,doid:8805,original,1. Management of hypertension.  2. Decrease angina frequency and increase exercise tolerance in patients with angina pectoris.  3. Control ventricular rate in patients with atrial fibrillation and a rapid ventricular response.  4. Reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable.  5. Prophylaxis of common migraine headache.   6. Management of familial or hereditary essential tremor.  7. Improves NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.  8. As an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors
Propranolol,525-66-6,Propranolol,DB00571,atrial fibrillation,doid:0060224,original,1. Management of hypertension.  2. Decrease angina frequency and increase exercise tolerance in patients with angina pectoris.  3. Control ventricular rate in patients with atrial fibrillation and a rapid ventricular response.  4. Reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable.  5. Prophylaxis of common migraine headache.   6. Management of familial or hereditary essential tremor.  7. Improves NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.  8. As an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors
Propranolol,525-66-6,Propranolol,DB00571,migraine,doid:6364,original,1. Management of hypertension.  2. Decrease angina frequency and increase exercise tolerance in patients with angina pectoris.  3. Control ventricular rate in patients with atrial fibrillation and a rapid ventricular response.  4. Reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable.  5. Prophylaxis of common migraine headache.   6. Management of familial or hereditary essential tremor.  7. Improves NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.  8. As an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors
Propranolol,525-66-6,Propranolol,DB00571,essential tremor,doid:4990,original,1. Management of hypertension.  2. Decrease angina frequency and increase exercise tolerance in patients with angina pectoris.  3. Control ventricular rate in patients with atrial fibrillation and a rapid ventricular response.  4. Reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable.  5. Prophylaxis of common migraine headache.   6. Management of familial or hereditary essential tremor.  7. Improves NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.  8. As an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors
Propranolol,525-66-6,Propranolol,DB00571,hypertrophic cardiomyopathy,doid:11984,original,1. Management of hypertension.  2. Decrease angina frequency and increase exercise tolerance in patients with angina pectoris.  3. Control ventricular rate in patients with atrial fibrillation and a rapid ventricular response.  4. Reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable.  5. Prophylaxis of common migraine headache.   6. Management of familial or hereditary essential tremor.  7. Improves NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.  8. As an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors
Propranolol,525-66-6,Propranolol,DB00571,proliferating infantile hemangiomas,,repositioned,Treatment of proliferating infantile hemangiomas requiring systemic therapy 
Protein C concentrate,,,,vein disease,doid:866,original,Ceprotin is indicated for patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans
Protein C concentrate,,,,purpura fulminans,doid:0060538,original,Ceprotin is indicated for patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans
Protein C concentrate,,,,purpura fulminans,doid:0060538,repositioned,For use in the prevention and treatment of purpura fulminans in meningococcemia.
Protirelin,24305-27-9,Protirelin,DB09421,**diagnostic agent**,,original,"1. As an adjunctive agent in the diagnostic assessment of thyroid function.  2. As an adjunct to evaluate the effectiveness of thyrotropin suppression with a particular dose of T4 in patients with nodular or diffuse goiter. 3.  Adjunctively, for adjustment of thyroid hormone dosage given to patients with primary hypothyroidism."
Protirelin,24305-27-9,Protirelin,DB09421,newborn respiratory distress syndrome,doid:12716,repositioned,Prevention of infant respiratory distress syndrome associated with prematurity.
Protirelin,24305-27-9,Protirelin,DB09421,amyotrophic lateral sclerosis,doid:332,repositioned,Treatment of amyothrophic lateral sclerosis.
Quinine sulfate,130-95-0,Quinine,DB00468,Plasmodium falciparum malaria,doid:14067,original,Treatment of uncomplicated Plasmodium falciparum malaria 
Quinine sulfate,130-95-0,Quinine,DB00468,malaria,doid:12365,repositioned,Treatment of malaria excluding Plasmodium faliparum
Rabbit anti-human thymocyte globulin (rATG),,Anti-thymocyte Globulin (Rabbit),DB00098,Transplant Rejection,,original,Treatment of renal transplant acute rejection in conjunction with concomitant immunosuppression.
Rabbit anti-human thymocyte globulin (rATG),,Anti-thymocyte Globulin (Rabbit),DB00098,Transplant Rejection,,repositioned,Induction treatment to prevent rejection and to minimize maintenance immunosupression in pediatric liver transplant recipients.
Rabbit anti-human thymocyte globulin (rATG),,Anti-thymocyte Globulin (Rabbit),DB00098,myelodysplastic syndrome,doid:0050908,repositioned,Treatment of myelodysplastic syndrome.
Raloxifene,84449-90-1,Raloxifene,DB00481,breast cancer,doid:1612,original,Breast and prostate cancer
Raloxifene,84449-90-1,Raloxifene,DB00481,prostate cancer,doid:10283,,Breast and prostate cancer
Raloxifene,84449-90-1,Raloxifene,DB00481,osteoporosis,doid:11476,repositioned,Osteoporosis
Rapamycin (mTOR) inhibitor,53123-88-9,Sirolimus,DB00877,Transplant Rejection,,original,Sirolimus is an immunosuppressive agent indicated for the prophylaxis of organ rejection in patients aged _13 years receiving renal transplants.
Rapamycin (mTOR) inhibitor,53123-88-9,Sirolimus,DB00877,tuberous sclerosis complex,,repositioned,Treatment of tuberous sclerosis complex.
Recombinant human C1 inhibitor,,C1 Esterase Inhibitor (Human),DB06404,angioedema,doid:1558,original,Berinert is a plasma-derived C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal or facial attacks of hereditary angioedema in adult and adolescent patients.
Recombinant human C1 inhibitor,,C1 Esterase Inhibitor (Human),DB06404,delayed graft function,,repositioned,Prevention and/or treatment of delayed graft function after solid organ transplantation.
Recombinant human C1 inhibitor,,C1 Esterase Inhibitor (Human),DB06404,capillary leak syndrome,doid:14400,repositioned,Treatment of capillary leakage syndrome 
Repository corticotropin or adrenocorticotropic hormone,12427-33-7,Corticotropin,DB01285,multiple sclerosis,doid:2377,original,Corticotropin is indicated for treatment of acute exacerbations of multiple sclerosis.
Repository corticotropin or adrenocorticotropic hormone,12427-33-7,Corticotropin,DB01285,infantile spasms,,repositioned,Treatment of infantile spasms
Ribavirin,36791-04-5,Ribavirin,DB00811,hepatitis C,doid:1883,original,Ribavirin tablets in combination with peginterferon alfa-2a are indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha.
Ribavirin,36791-04-5,Ribavirin,DB00811,respiratory syncytial virus infectious disease,doid:1273,original,VIRAZOLE (ribavirin powder for solution) is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus.
Ribavirin,36791-04-5,Ribavirin,DB00811,hemorrhagic fever with renal syndrome,doid:11266,repositioned,Treatment of hemorrhagic fever with renal syndrome.
Rifabutin,72559-06-9,Rifabutin,DB00615,Mycobacterium avium complex disease,doid:2755,original,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.
Rifabutin,72559-06-9,Rifabutin,DB00615,Mycobacterium avium complex disease,doid:2755,repositioned,Treatment of disseminated Mycobacterium avium complex disease.
Riluzole,1744-22-5,Riluzole,DB00740,amyotrophic lateral sclerosis,doid:332,original,Treatment of patients with amyotrophic lateral sclerosis. 
Riluzole,1744-22-5,Riluzole,DB00740,Huntington's disease,doid:12858,repositioned,Treatment of Huntington's disease.
Risedronate sodium,105462-24-6,Risedronate,DB00884,osteoporosis,doid:11476,original,1.Treatment and prevention of postmenopausal osteoporosis; 2.Treatment to increase bone mass in men with osteoporosis; 3.Treatment and prevention of glucocorticoid-induced osteoporosis; 4.Treatment of Paget_s disease .
Risedronate sodium,105462-24-6,Risedronate,DB00884,mammary Paget's disease,doid:3443,original,1.Treatment and prevention of postmenopausal osteoporosis; 2.Treatment to increase bone mass in men with osteoporosis; 3.Treatment and prevention of glucocorticoid-induced osteoporosis; 4.Treatment of Paget_s disease .
Risedronate sodium,105462-24-6,Risedronate,DB00884,osteogenesis imperfecta,doid:12347,repositioned,Treatment of patients with osteogenesis imperfecta.
Rituximab,174722-31-7,Rituximab,DB00073,rheumatoid arthritis,doid:7148,original,"Rituxan (rituximab), in combination with methotrexate, is also indicated for adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies."
Rituximab,174722-31-7,Rituximab,DB00073,non-Hodgkin lymphoma,doid:0060060,original,Treatment of patients with:1. Non-Hodgkin_s Lymphoma. 2. Chronic Lymphocytic Leukemia.
Rituximab,174722-31-7,Rituximab,DB00073,chronic lymphocytic leukemia,doid:1040,,Treatment of patients with:1. Non-Hodgkin_s Lymphoma. 2. Chronic Lymphocytic Leukemia.
Rituximab,174722-31-7,Rituximab,DB00073,autoimmune thrombocytopenic purpura,doid:8924,repositioned,Treatment of immune thrombocytopenic purpura
Rituximab,174722-31-7,Rituximab,DB00073,vasculitis,doid:865,repositioned,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)."
Sermorelin acetate,86168-78-7,Sermorelin,DB00010,growth failure,,original,Treatment of idiopathic or organic growth hormone deficiency in children with growth failure. 
Sermorelin acetate,86168-78-7,Sermorelin,DB00010,infertility,doid:5223,repositioned,Adjunct to gonadotropin therapy in the induction of ovulation in women with anovulatory or oligo-ovulatory infertility who fail to ovulate in response to adequate treatment with clomiphene citrate alone and gonadotropin therapy alone.
Sibutramine,106650-56-0,Sibutramine,DB01105,mental depression,doid:1596,original,Depression
Sibutramine,106650-56-0,Sibutramine,DB01105,obesity,doid:9970,repositioned,Obesity
Sildenafil,139755-83-2,Sildenafil,DB00203,intermediate coronary syndrome,doid:8805,original,Angina
Sildenafil,139755-83-2,Sildenafil,DB00203,impotence,doid:1875,repositioned,Male erectile dysfunction
Sildenafil,139755-83-2,Sildenafil,DB00203,pulmonary hypertension,doid:6432,repositioned,pulmonary hypertension
Sodium benzoate and Sodium phenylacetate 10%/10% Injection,,,,ornithine translocase deficiency,doid:0050720,original,Adjunctive therapy in the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.
Sodium benzoate and Sodium phenylacetate 10%/10% Injection,,,,hepatic encephalopathy,doid:13413,repositioned,Treatment of grade III and VI hepatic encephalopathy
Sodium phenylbutyrate,1716-12-7,Sodium phenylbutyrate,DB06819,urea cycle disorder,doid:9267,original,"Adjunctive therapy in the chronic managment of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase."
Sodium phenylbutyrate,1716-12-7,Sodium phenylbutyrate,DB06819,malignant glioma,doid:3070,repositioned,"For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.  "
Sodium phenylbutyrate,1716-12-7,Sodium phenylbutyrate,DB06819,sickle cell anemia,doid:10923,repositioned,"Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy."
Sodium phenylbutyrate,1716-12-7,Sodium phenylbutyrate,DB06819,acute promyelocytic leukemia,doid:0060318,repositioned,Treatment of acute promyelocytic leukemia.
Sodium phenylbutyrate,1716-12-7,Sodium phenylbutyrate,DB06819,spinal muscular atrophy,doid:12377,repositioned,Treatment of spinal muscular atrophy
Sodium thiosulfate,7772-98-7 ,Sodium thiosulfate,DB09499,nephrotoxicity,,original,"Used in the treatment of cyanide poisoning. Sodium thiosulfate may be used in the management of extravasation of chlormethine and some other antineoplastics. It is also used to inactivate some antineoplastics before disposal. Sodium thiosulfate, given by intravenous infusion, has also been investigated for reducing the systemic toxicity of some antineoplastics. It has been reported to reduce the incidence of nephrotoxicity associated with intraperitoneal cisplatin."
Sodium thiosulfate,7772-98-7 ,Sodium thiosulfate,DB09499,ototoxicity,,repositioned,Prevention of platinum-induced ototoxicity in pediatric patients
Somatropin,12629-01-5,Somatropin recombinant,DB00052,growth hormone deficiency,,original,As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.
Somatropin,12629-01-5,Somatropin recombinant,DB00052,Prader-Willi syndrome,doid:11983,original,Long-term treatment of pediatric patients who have growth failure due to Prader-Willi syndrome.
Somatropin,12629-01-5,Somatropin recombinant,DB00052,kidney failure,doid:1074,original,Treatment of children with growth failure associated with chronic renal insufficency.
Somatropin,12629-01-5,Somatropin recombinant,DB00052,short bowel syndrome,doid:10605,original,Treatment of short bowel syndrome in patients receiving specialized nutritional support
Somatropin,12629-01-5,Somatropin recombinant,DB00052,Turner syndrome,doid:3491,original,Treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed.
Somatropin,12629-01-5,Somatropin recombinant,DB00052,Noonan syndrome,doid:3490,original,Treatment of short stature in patients with Noonan syndrome
Somatropin,12629-01-5,Somatropin recombinant,DB00052,infertility,doid:5223,repositioned,"Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures."
Somatropin,12629-01-5,Somatropin recombinant,DB00052,burns,,repositioned,For the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.
Sorafenib,284461-73-0,Sorafenib,DB00398,renal cell carcinoma,doid:4450,original,Treatment of patients with advanced renal cell carcinoma 
Sorafenib,284461-73-0,Sorafenib,DB00398,hepatocellular carcinoma,doid:684,original,Treatment of unresectable hepatocellular carcinoma 
Sorafenib,284461-73-0,Sorafenib,DB00398,melanoma,doid:1909,repositioned,Treatment of stage IIB through stage IV melanoma
Succimer,304-55-2,Succimer,DB00566,lead poisoning,,original,Treatment of lead poisoning in children pediatric patients with blood lead levels above 45 _g/dL.
Succimer,304-55-2,Succimer,DB00566,cystinuria,doid:9266,repositioned,Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.
Succimer,304-55-2,Succimer,DB00566,mecury intoxication,,repositioned,Treatment of mercury intoxication.
Sucralfate,54182-58-0,Sucralfate,DB00364,duodenal ulcer,doid:1724,original,1. Short-term treatment (up to 8 weeks) of active duodenal ulcer. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing ofacute ulcers.
Sucralfate,54182-58-0,Sucralfate,DB00364,,,repositioned,Treatment of oral complications of chemotherapy in bone marrow transplant patients.
Sucralfate,54182-58-0,Sucralfate,DB00364,stomatitis,doid:9637,repositioned,Treatment of oral mucositis and stomatitis following radiation therapy for head and neck cancer.
Sucralfate,54182-58-0,Sucralfate,DB00364,epidermolysis bullosa,doid:2730,repositioned,Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.
Synthetic human secretin,,Secretin,DB00021,**imaging**,,original,Facilitation of the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP).
Synthetic human secretin,,Secretin,DB00021,**diagnostic agent**,,repositioned,For use in conjunction with diagnostic procedures (excluding ERCP) for pancreatic disorders to increase pancreatic fluid secretion.
Tadalafil,171596-29-5,Tadalafil,DB00820,inflammation,,original,Inflammation and cardiovascular disease
Tadalafil,171596-29-5,Tadalafil,DB00820,heart disease,doid:114,original,Inflammation and cardiovascular disease
Tadalafil,171596-29-5,Tadalafil,DB00820,impotence,doid:1875,repositioned,Male erectile dysfunction
Temozolomide,85622-93-1,Temozolomide,DB00853,glioblastoma multiforme,doid:3068,original,Treatment of adult patients with newly diagnosed glioblastoma multiforme concomitatly with radiotherapy and then as maintenance treatment
Temozolomide,85622-93-1,Temozolomide,DB00853,grade III astrocytoma,doid:3078,original,"Treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine."
Temozolomide,85622-93-1,Temozolomide,DB00853,melanoma,doid:1909,repositioned,Treatment of advanced metastatic melanoma.
Tenecteplase,191588-94-0,Tenecteplase,DB00031,myocardial infarction,doid:5844,original,Use in the reduction of mortality associated with acute myocardialinfarction.
Tenecteplase,191588-94-0,Tenecteplase,DB00031,,,repositioned,Restore function to hemodialysis catheters
Tenofovir disoproxil fumarate,147127-20-6,Tenofovir,DB00300,human immunodeficiency virus infectious disease,doid:526,original,It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and adolescents. It is indicated for the treatment of chronic hepatitis B in adults. 
Tenofovir disoproxil fumarate,147127-20-6,Tenofovir,DB00300,hepatitis B,doid:2043,original,It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and adolescents. It is indicated for the treatment of chronic hepatitis B in adults. 
Tenofovir disoproxil fumarate,147127-20-6,Tenofovir,DB00300,human immunodeficiency virus infectious disease,doid:526,repositioned,Treatment of pediatric HIV infection. 
Testosterone,58-22-0,Testosterone,DB00624,weight loss,,repositioned,For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.
Testosterone propionate ointment 2%,58-22-0,Testosterone,DB00624,hypogonadism,doid:1924,original,"Testosterone gel is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone:_Primary Hypogonadism (Congenital or Acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. _Hypogonadotropic Hypogonadism (Congenital or Acquired) - idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation."
Testosterone propionate ointment 2%,58-22-0,Testosterone,DB00624,vulvar dystrophy,doid:14292,repositioned,Treatment of vulvar dystrophies.
Tetrabenazine,58-46-8,Tetrabenazine,DB04844,Huntington's disease,doid:12858,original,Treatment of chorea associated with Huntington's disease
Tetrabenazine,58-46-8,Tetrabenazine,DB04844,Gilles de la Tourette syndrome,doid:11119,repositioned,"Treatment of Tourette's Syndrome in school-age children, ages 5-16."
Tetrabenazine,58-46-8,Tetrabenazine,DB04844,tardive dyskinesia,,repositioned,Treatment of moderate/severe tardive dyskinesia.
Thalidomide,50-35-1,Thalidomide,DB01041,erythema nodosum leprosum,,original,Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences.
Thalidomide,50-35-1,Thalidomide,DB01041,multiple myeloma,doid:9538,original,Treatment of patients with newly diagnosed multiple myeloma
Thalidomide,50-35-1,Thalidomide,DB01041,graft vs host disease,,repositioned,Prevention of graft versus host disease in patients receiving bone marrow transplantation.
Thalidomide,50-35-1,Thalidomide,DB01041,lepromatous leprosy,doid:10887,repositioned,Treatment and maintenance of reactional lepromatous leprosy.
Thalidomide,50-35-1,Thalidomide,DB01041,Crohn's disease,doid:8778,repositioned,Treatment of Crohn's disease.
Thalidomide,50-35-1,Thalidomide,DB01041,Kaposi's sarcoma,doid:8632,repositioned,Treatment of Kaposi's sarcoma.
Thalidomide,50-35-1,Thalidomide,DB01041,myelodysplastic syndrome,doid:0050908,repositioned,Treatment of Myelodysplastic Syndrome 
Thalidomide,50-35-1,Thalidomide,DB01041,brain cancer,doid:1319,repositioned,Treatment of primary brain malignancies.
Thalidomide,50-35-1,Thalidomide,DB01041,aphthous stomatitis,doid:9663,repositioned,"Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients."
Thalidomide,50-35-1,Thalidomide,DB01041,Mycobacterium avium complex disease,doid:2755,repositioned,Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.
Thalidomide,50-35-1,Thalidomide,DB01041,tuberculosis,doid:399,repositioned,Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.
Thiotepa,52-24-4,Thiotepa,DB04572,ovary adenocarcinoma,doid:3713,original,"Thiotepa has been tried with varying results in the palliation of a wide variety of neoplastic diseases. However, the most consistent results have been seen in the following tumors: Adenocarcinoma of the ovary. While now largely superseded by other treatments, thiotepa has been effective against other lymphomas, such as lymphosarcoma and Hodgkin's disease."
Thiotepa,52-24-4,Thiotepa,DB04572,lymphoma,doid:0060058,original,"Thiotepa has been tried with varying results in the palliation of a wide variety of neoplastic diseases. However, the most consistent results have been seen in the following tumors: Adenocarcinoma of the ovary. While now largely superseded by other treatments, thiotepa has been effective against other lymphomas, such as lymphosarcoma and Hodgkin's disease."
Thiotepa,52-24-4,Thiotepa,DB04572,lymphosarcoma,doid:8675,original,"Thiotepa has been tried with varying results in the palliation of a wide variety of neoplastic diseases. However, the most consistent results have been seen in the following tumors: Adenocarcinoma of the ovary. While now largely superseded by other treatments, thiotepa has been effective against other lymphomas, such as lymphosarcoma and Hodgkin's disease."
Thiotepa,52-24-4,Thiotepa,DB04572,Hodgkin's lymphoma,doid:8567,original,"Thiotepa has been tried with varying results in the palliation of a wide variety of neoplastic diseases. However, the most consistent results have been seen in the following tumors: Adenocarcinoma of the ovary. While now largely superseded by other treatments, thiotepa has been effective against other lymphomas, such as lymphosarcoma and Hodgkin's disease."
Thiotepa,52-24-4,Thiotepa,DB04572,breast adenocarcinoma,doid:3458,original,"Thiotepa has been tried with varying results in the palliation of a wide variety of neoplastic diseases. However, the most consistent results have been seen in the following tumors:Adenocarcinoma of the breast; For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities; For the treatment of superficial papillary carcinoma of the urinary bladder. "
Thiotepa,52-24-4,Thiotepa,DB04572,bladder urothelial papillary carcinoma,doid:6975,original,"Thiotepa has been tried with varying results in the palliation of a wide variety of neoplastic diseases. However, the most consistent results have been seen in the following tumors:Adenocarcinoma of the breast; For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities; For the treatment of superficial papillary carcinoma of the urinary bladder. "
Thiotepa,52-24-4,Thiotepa,DB04572,**transplant preparation**,,repositioned,Conditioning treatment prior to hematopoietic stem cell transplantation
Tiotropium bromide,186691-13-4,Tiotropium,DB01409,chronic obstructive pulmonary disease,doid:3083,original,"Tiotropium bromide inhalation powder is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is also indicated to reduce exacerbations in COPD patients."
Tiotropium bromide,186691-13-4,Tiotropium,DB01409,cystic fibrosis,doid:1485,repositioned,To improve pulmonary function in conjunction with standard therapy in the management of patients with cystic fibrosis
Tobramycin,32986-56-4,Tobramycin,DB00684,primary bacterial infectious disease,doid:0050338,original,TOBI© is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.
Tobramycin,32986-56-4,Tobramycin,DB00684,bronchiectasis,doid:9563,repositioned,Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.
Tofisopam,22345-47-7,Tofisopam,DB08811,anxiety disorder,doid:2030,original,Anxiety-related conditions
Tofisopam,22345-47-7,Tofisopam,DB08811,irritable bowel syndrome,doid:9778,repositioned,Irritable bowel syndrome
Topiramate,97240-79-4,Topiramate,DB00273,epilepsy,doid:1826,original,Epilepsy
Topiramate,97240-79-4,Topiramate,DB00273,obesity,doid:9970,repositioned,Obesity
Toremifene,89778-26-7,Toremifene,DB00539,breast cancer,doid:1612,original,Treatment of metastatic breast cancer in postmenopausal women with estrogen positive or receptor unknown tumors.
Toremifene,89778-26-7,Toremifene,DB00539,Desmoid tumor,,repositioned,Treatment of desmoid tumors.
Tramadol hydrochloride,27203-92-5,Tramadol,DB00193,**Analgesic**,,original,Management of moderate to moderately severe pain in adults.
Tramadol hydrochloride,27203-92-5,Tramadol,DB00193,postherpetic neuralgia,,repositioned,Management of postherpetic neuralgia
Tramadol hydrochloride,27203-92-5,Tramadol,DB00193,neuropathy,doid:870,repositioned,Treatment of painful HIV-associated neuropathy
Tranexamic acid,1197-18-8,Tranexamic Acid,DB00302,inherited blood coagulation disease,doid:2214,original,Tranexamic acid Injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.
Tranexamic acid,1197-18-8,Tranexamic Acid,DB00302,female reproductive system disease,doid:229,original,Tranexamic acid tablets is indicated for the treatment of cyclic heavy menstrual bleeding
Tranexamic acid,1197-18-8,Tranexamic Acid,DB00302,angioedema,doid:1558,repositioned,Treatment of hereditary angioneurotic edema.
Tranexamic acid,1197-18-8,Tranexamic Acid,DB00302,,,repositioned,Treatment of patients undergoing prostatectomy where there is hemorrhage or risk of hemorrhage as a result of increased fibrinolysis or fibrinogenolysis.
Trastuzumab,180288-69-1,Trastuzumab,DB00072,breast cancer,doid:1612,original,"As a single agent it is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein and who have received one or more chemotherapy regimens for their metastatic disease. In combination with paclitaxel, it is indicated for treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein and who have not received chemotherapy for their metastatic disease. "
Trastuzumab,180288-69-1,Trastuzumab,DB00072,stomach cancer,doid:10534,repositioned,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction"
Trastuzumab,180288-69-1,Trastuzumab,DB00072,pancreatic cancer,doid:1793,repositioned,Treatment of patients with pancreatic cancer that overexpress p185HER2.  
Tretinoin,302-79-4,Tretinoin,DB00755,acute promyelocytic leukemia,doid:0060318,original,Tretinoin capsule is indicated for induction of remission in patients with acute promyelocytic leukemia who are refractory to or unable to tolerate anthracycline based cytotoxic chemotherapeutic regimens.
Tretinoin,302-79-4,Tretinoin,DB00755,cutaneous T cell lymphoma,doid:0060061,repositioned,Treatment of T-cell  non-Hodgkin's lymphoma
Tretinoin,302-79-4,Tretinoin,DB00755,leukemia,doid:1240,repositioned,Treatment of acute and chronic leukemia.
Tretinoin,302-79-4,Tretinoin,DB00755,squamous cell neoplasm,doid:3168,repositioned,Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.
Trimetrexate,52128-35-5,Trimetrexate,DB01157,pneumocystosis,doid:11339,original,"Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe Pneumocystis carinii pneumonia in immunocompromised patients including patients with the acquired immunodeficiency syndrome, who are intolerant of, or are refractory to, trimethoprim-sulfamethoxazole therapy or for whom trimethoprim-sulfamethoxazole is contraindicated."
Trimetrexate,52128-35-5,Trimetrexate,DB01157,carcinoma,doid:305,repositioned,"Treatment of metastatic carcinoma of the head and neck (i.e. buccal cavity, pharynx, and larynx)."
Trimetrexate,52128-35-5,Trimetrexate,DB01157,osteosarcoma,doid:3347,repositioned,Treatment of metastatic osteogenic sarcoma.
Trimetrexate,52128-35-5,Trimetrexate,DB01157,pancreatic adenocarcinoma,doid:4074,repositioned,Treatment of pancreatic adenocarcinoma.
Trimetrexate,52128-35-5,Trimetrexate,DB01157,non-small cell lung carcinoma,doid:3908,repositioned,Treatment of patients with advanced non-small cell carcinoma of the lung.
Triptorelin pamoate,57773-63-4,Triptorelin,DB06825,prostate cancer,doid:10283,original,Palliative treatment of advanced prostate cancer.
Triptorelin pamoate,57773-63-4,Triptorelin,DB06825,ovary epithelial cancer,doid:2152,repositioned,For use in the palliative treatment of advanced ovarian carcinoma of epithelial origin.
Urofollitropin,146479-72-3,Urofollitropin,DB00094,anovulation,doid:3781,original,"Bravelle administered SC or IM in conjunction with hCG, is indicated for: 1.ovulation induction in patients; 2. multiple follicular development (controlled ovarian stimulation) during ART cycles, in patients who have previously received pituitary suppression."
Urofollitropin,146479-72-3,Urofollitropin,DB00094,polycystic ovary syndrome,doid:11612,original,For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.
Urofollitropin,146479-72-3,Urofollitropin,DB00094,male infertility,doid:12336,repositioned,"For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism."
Ursodiol,128-13-2,Ursodeoxycholic acid,DB01586,cholelithiasis,doid:10211,original,"1. Ursodiol is indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. 2.Ursodiol is indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss."
Ursodiol,128-13-2,Ursodeoxycholic acid,DB01586,primary biliary cirrhosis,doid:12236,original,URSO 250© and URSO Forte© (ursodiol) tablets are indicated for the treatment of patients with primary biliary cirrhosis.
Ursodiol,128-13-2,Ursodeoxycholic acid,DB01586,cystic fibrosis,doid:1485,repositioned,Treatment of cystic fibrosis liver disease
"Valproic acid, sodium",99-66-1,Valproic Acid,DB00313,bipolar disorder,doid:3312,original,"Divalproex sodium extended-release is indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features. It is indicated for prophylaxis of migraine headaches in adults. It is indicated as monotherapy and adjunctive therapy in the treatment of adults and children 10 years of age or older with complex partial seizures that occur either in isolation or in association with other types of seizures. It is also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures in adults and children 10 years of age or older, and adjunctively in adults and children 10 years of age or older with multiple seizure types that include absence seizures."
"Valproic acid, sodium",99-66-1,Valproic Acid,DB00313,migraine,doid:6364,original,"Divalproex sodium extended-release is indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features. It is indicated for prophylaxis of migraine headaches in adults. It is indicated as monotherapy and adjunctive therapy in the treatment of adults and children 10 years of age or older with complex partial seizures that occur either in isolation or in association with other types of seizures. It is also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures in adults and children 10 years of age or older, and adjunctively in adults and children 10 years of age or older with multiple seizure types that include absence seizures."
"Valproic acid, sodium",99-66-1,Valproic Acid,DB00313,epilepsy,doid:1826,original,"Divalproex sodium extended-release is indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features. It is indicated for prophylaxis of migraine headaches in adults. It is indicated as monotherapy and adjunctive therapy in the treatment of adults and children 10 years of age or older with complex partial seizures that occur either in isolation or in association with other types of seizures. It is also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures in adults and children 10 years of age or older, and adjunctively in adults and children 10 years of age or older with multiple seizure types that include absence seizures."
"Valproic acid, sodium",99-66-1,Valproic Acid,DB00313,familial adenomatous polyposis,doid:0050424,repositioned,Treatment of familial adenomatous polyposis
"Valproic acid, sodium",99-66-1,Valproic Acid,DB00313,fragile X syndrome,doid:14261,repositioned,Treatment of fragile X syndrome.
Vorinostat,149647-78-9,Vorinostat,DB02546,cutaneous T cell lymphoma,doid:0060061,original,"Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma  who have progressive, persistant or recurrent disease on or following two systemic therapies."
Vorinostat,149647-78-9,Vorinostat,DB02546,malignant mesothelioma,doid:1790,repositioned,Treatment of mesothelioma
Vorinostat,149647-78-9,Vorinostat,DB02546,multiple myeloma,doid:9538,repositioned,Treatment of multiple myeloma
Zidovudine,30516-87-1,Zidovudine,DB00495,cancer,doid:162,original,Cancer
Zidovudine,30516-87-1,Zidovudine,DB00495,human immunodeficiency virus infectious disease,doid:526,repositioned,HIV/AIDS
Zidovudine,30516-87-1,Zidovudine,DB00495,acquired immunodeficiency syndrome,doid:635,repositioned,HIV/AIDS
buprenorphine,52485-79-7,Buprenorphine,DB00921,**Analgesic**,,original,pain
buprenorphine,52485-79-7,Buprenorphine,DB00921,opiate dependence,doid:2559,repositioned,opiate addiction
bupropion,34841-39-9,Bupropion,DB01156,mental depression,doid:1596,original,depression
bupropion,34841-39-9,Bupropion,DB01156,nicotine dependence,doid:0050742,repositioned,smoking cessation
doxycycline,564-25-0,Doxycycline,DB00254,bacterial infectious disease,doid:104,original,bacterial infection
doxycycline,564-25-0,Doxycycline,DB00254,periodontitis,doid:824,repositioned,periodontitis
miltefosine,58066-85-6,Miltefosine,DB09031,cancer,doid:162,original,cancer
miltefosine,58066-85-6,Miltefosine,DB09031,leishmaniasis,doid:9065,repositioned,leishmaniasis
ropinirole,91374-21-9,Ropinirole,DB00268,hypertension,doid:10763,original,hypertension
ropinirole,91374-21-9,Ropinirole,DB00268,Parkinson's disease,doid:14330,repositioned,Parkinson's disease
ropinirole,91374-21-9,Ropinirole,DB00268,restless legs syndrome,doid:0050425,repositioned,restless leg syndrome
